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ABSTRACT 
 
Ruthenium Nitrosyl Salen and Salophen PhotoNORMS: Biological Studies and Applications 
towards Small Molecule Delivery Platforms 
 
by 
 
Meredith Anne Crisalli 
 
Nitric oxide (NO) is an endogenously produced small molecule involved in neural 
transmission, immune response, and blood pressure regulation. The radical nature of NO has 
also been studied for its ability to increase radiation damage in hypoxic cells, thus improving 
radiation chemotherapy.  In this vein, we are committed to generating molecules that utilize 
an external trigger to allow for controlled release of NO in biology.  
Photochemical release of NO allows for specific location, timing, and dosage of a drug 
and has the potential to limit wide spread side-effects common to chemotherapy treatments. 
Several novel ruthenium nitrosyls have been synthesized and studied for their photoactive 
nitric oxide release. Compounds were characterized by mass spectroscopy, NMR, UV-visible 
spectra, IR, elemental analysis, photochemical reactivity and ability to release NO. Quantum 
yields and efficiency measurements were conducted by monitoring the moles of NO produced 
due to light irradiation. The release of NO was detected by a Nitric Oxide Analyzer in real 
time.  
  viii  
Two major compounds will be discussed, a water soluble, water stable ruthenium 
nitrosyl for applications in biological systems and a hydrophobic ruthenium nitrosyl variant 
which was infused into a polymer matrix with up-converting nanoparticles (UCNP). The 
water soluble compound Ru(NO)(salen-CO2H)Cl 1, has been studied for its photochemistry, 
cytotoxicity on a murine melanoma cancer cell line, and vasodilation in murine aortic rings. 
The hydrophobic compound, Ru(NO)(salophen)Cl, was loaded into a polymer matrix with 
UCNP, utilizing unique properties of UCNPs to shift the excitation wavelength into the near 
infrared region, where there is better tissue penetration of light. This document contains the 
synthetic, photochemical, and studies on the efficiency of NO release for each compound. 
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Chapter 1. Introduction 
1.1  NO in Biology 
In 1987 nitric oxide (NO) was observed to be an endogenously produced small 
molecule for biological signaling.1, 2 Once thought to solely be a toxic inorganic gaseous 
molecule, NO has now been found to possess a myriad of roles in biology, many of which are 
concentration dependent and closely regulated by the body. As a signaling molecule, NO is 
responsible for smooth muscle relaxation, vasodilation, and neurotransmission at nanomolar 
concentrations.3 NO is also generated as an immune response to pathogens in much higher 
concentrations, inducing cell death.4 NO can be generated and utilized in three separate 
regulatory roles, by three different nitric oxide synthase enzymes: iNOS (immune system), 
eNOS (endothelial tissue), and nNOS (nervous system). 
 One of the more pertinent biological applications of NO is vasodilation. NO is 
produced in endothelium cells from oxidation of L-arginine to L-citrulline, a process catalyzed 
by the P450 type enzyme eNOS.5 The resulting NO then diffuses through smooth muscle 
tissue and binds to the iron heme of soluble guanylyl cyclase (sGC), the enzyme that catalyzes 
conversion from guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). 
The net result is the NO-triggered induction of arterial vaso-relaxation.6  
1.2 NO in Cancer 
The rapid growth of tumors causes the formation of irregular blood vessels which leads 
to portions of a tumor being oxygen deficient. The lack of oxygen results in anaerobic 
respiration and the buildup of lactic acid within the tumor, lowering the pH.7 Primary and 
metastatic tumors have both been shown to exhibit slightly acidic pH values relative to the pH 
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observed in normal, healthy tissue.7 The acidic and hypoxic environments in tumors inhibits 
radiation induced apoptosis and the efficacy of radiation therapy.  
NO has also been shown to modulate the growth of tumors, exhibiting both tumoricidal 
and tumor promoting behavior with strong dependence upon the concentration and location 
of up-regulation or release of NO. In low concentrations, NO helps cell proliferation and 
protects against apoptosis.8 9 Alternatively, increased NO concentrations have been observed 
to suppress cellular respiration and DNA synthesis and shift metabolic pathways to remove 
iron storage in tumors through immune response.10,11,12 The impacts of DNA synthesis 
suppression are attributed to either radical attack damaging DNA or binding to the DNA repair 
mechanisms, which can result in gene mutations or apoptosis at mM concentrations.12 
The radical character of NO has proven useful as a -radiation sensitizer, a valuable 
feature in the radiotherapy of hypoxic tumors that have reduced radiation sensitivity as a result 
of their low oxygen concentrations.13 The generation of NO at a hypoxic tumor site as both a 
vasodilator and a radiation sensitizer increases both the oxygen concentration and the 
concentration of radiation sensitizers, specifically NO and O2. Owing to the fast diffusion and 
short lifetime of NO, radiation treatment and NO production would need to be administered 
simultaneously. The ability of photoactive releasing molecules to control location, timing, and 
dosage is ideal for this form of photo dynamic therapy (PDT).   
1.3 Enemark-Feltham Notation 
 Nitric oxide as a free radical, depicted as NO• has the potential to either gain an 
electron to become NO-, or lose an electron to form NO+. With triple bond character, NO+ will 
bind linearly to metals with an MNO bond angle of 180° while the valance bond structure for 
NO- will exhibit a MNO bond angle of 120°, designated as bent. Upon binding with transition 
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metals however, the NO bond can be directed to a different binding mode due to ligand field 
effects changing the oxidation state of the metal.14 The formal charge and electron 
assignments become more difficult when NO binds to a metal with several possible oxidation 
states and results in two isoelectronic designations, for example Ru(II)-NO+ and Ru(III)-NO• 
as resonance forms.  
Enemark and Feltham therefore devised a notation in order to simplify assignment of 
the oxidation state of both metal and NO ligand. Total electrons in the system are assumed to 
belong to the metal-NO conjugate and is depicted as {M-NO}n where n is equal to the total 
valance d electrons from the metal plus the * electron contribution from the nitrosyl. The 
example above can therefore be written as {Ru-NO}6 where 6 electrons are shared between 
the metal and nitrosyl. Moreover, the Enemark-Feltham notation allows for the ambiguity of 
a metal nitrosyl bond angle (M-N-O) that is not completely linearly bound at 180° nor 
completely in the bent form at 120°. 
1.4 Photochemistry of NO Releasing Complexes 
 Copious numbers of metal complexes have been studied for their NO releasing 
capabilities. The main thrust of the research has focused on a few metals capable of releasing 
NO photochemically known as photoactive nitric oxide releasing molecules or photoNORMs. 
Furthermore, the ideal wavelength for biological applications occurs where deoxygenated 
hemoglobin, melanin, and water do not absorb strongly and tissue penetration is deepest. This 
leaves a therapeutic window between 700-1100 nm.15 Initial studies focused employing iron 
complexes, primarily due its earth abundance and common use in heme structures, followed 
by chromium, ruthenium, and more recently, manganese. The structures of several 
photoNORMs that have been well-studied are included in Figure 1.1. 
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The canonical NO releasing complexes were first reported in 1858 with the studies of 
M L. Roussin. Roussin prepared a new synthetic iron sulfur cluster by reacting nitroprusside 
with sulfur to produce an iron sulfur salt.16 The resulting complexes, Roussin’s Red Salt 
dianion Fe2S2(NO)4
2- (RRS) and Roussin’s black salt Fe4S3(NO)7- (RBS), were observed to 
release NO upon heating or photochemical excitation. They also possess the added advantage 
of water solubility.17 The large number of NO ligands sequestered in the inactivated complex 
allows for multiple moles of NO to be released per mole of iron compound upon thermal 
heating or photochemical activation. In experiments with hypoxic V79 Chinese hamster lung 
fibroblast cancer cells, RRS was proven to increase the potency of gamma-radiation therapy 
when cells were exposed to light and NO was released.18 Photoactivated release at 365 nm of 
NO is quite high for RBS, with quantum yields ranging from 0.09 when irradiated in pH 10 
buffer to 0.40 in acetone.19 Unfortunately, these compounds are thermally unstable and 
decompose over time at biological temperatures, and are unstable to oxygen which severely 
limits biological applications. With consideration of the instability of RRS and RBS, 
Roussin’s red salt esters (RSE) were synthesized to help stabilize the Fe-S-Fe bonds while 
retaining photoactive NO releasing abilities.20 The RSE complexes reported also retained 
partial oxygen and thermal sensitivity as the parent compounds with 10% decomposition in 
aerated solvent over 30 hours in the dark.20    Chromium species have also displayed great 
ability to release NO. The most studied being Cr(III)(cyclam)(ONO)2
+, ("CrONO"), which 
possesses a ligand field absorption band allowing for sufficient absorbance for photoactivation 
at 550 nm and a quantum yield for NO release of 27% upon irradiation at 436 nm.21 It has 
been shown to induce vasodilation in porcine arteries when excited at 470 nm and has 
exceptional stability in the dark over time. Kinetic studies of the compound have shown that 
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the release of NO is dependent on the presence of oxygen or glutathione as a trapping agent, 
the highly reducing environment of tumors can therefore be used to trap the photoproduct and 
minimize recombination with NO.7 
 Mascharak and coworkers have been studying manganese nitrosyl derivatives with di-
carboxiamine ligands. One such compound, with a quinolyl-carboxamide, 
[(PaPy2Q)Mn(NO)](ClO4), displays an absorbance maxima at 670 nm in water and a molar 
absorptivity of 450 M-1 cm-1, indicating valuable photochemical properties. Indeed, the 
improved extinction coefficient and lability of the manganese-NO bond afford a quantum 
yield of NO release at 69.4% when irradiated at 550 nm. However, it should be noted that 
these results were determined in extremely high concentrations with a high intensity of light, 
due to limitations in actinometry, therefore <99.999% of light was assumed to be absorbed 
for quantum yield calculations.22 Moreover, the carboxamide manganese nitrosyl has not been 
exposed directly to cells but rather embedded into a polymer matrix to prevent complex 
release, indicating possible cytotoxicity of the free complex. Therefore continuing research 
has focused on the encapsulation of the compound within a porous Si-MCM-41 structure for 
the purpose of treating drug resistant bacteria with high concentrations of NO upon irradiation 
to induce apoptosis. This method of NO treatment has shown positive results in cell death 
when bacteria is exposed to 15-50 mg of the 2% wt loading MCM-41.23  
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Figure 1.1. PhotoNORMs: Roussin's Red Salt (RRS), Roussin's Black Salt (RBS), Roussin's 
Red Salt Ester (RSE), Cr(cyclam)(ONO)2
+, and [PaPy2Q)MN(NO)](ClO4). 
1.5 Ruthenium nitrosyls 
Ruthenium centered nitrosyls have been extensively studied due to efficient release of 
NO upon light irradiation (reference). DFT calculations have shown the release of NO to be 
associated with excitation of the metal-to-ligand charge transfer (MLCT) which increases 
electron density in the *NO orbital, effectively promoting NO release.24 Initially synthesized 
as a pro-catalyst for the epoxidation of alkenes25 and as Lewis acid catalysts that had to be 
shielded from light during experiments,26 the Ru(NO)(salen)Cl [salen = N,N′-bis-
(salicylidiene)ethylenediaminato] compound was studied in this laboratory as a 
photochemical  NO precursor, informing possible therapeutic properties of such complexes.  
 Chelating ligands with donor atoms of nitrogen, oxygen, phosphorus, and sulfur help 
to stabilize the ruthenium compounds in the Ru(II) oxidation state. Therefore ligands such as 
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Schiff bases, porphyrins, and di-carboxiamines have been studied as stable NO releasing 
molecules.27 Di-carboxiamines have shown great promise with quantum yields for NO release 
ranging from 5% up to 18% with irradiation wavelengths below 400 nm (ultraviolet 
excitation), however these compounds are not water soluble.27  
Efforts have been made to append a fluorescent dye tether to the axial position of 
carboxiamine ligands to allow for metal-nitrosyl complex tracking.28 While adding such 
approaches have shown potential promise, the dye dissociates in cell cultures by 
approximately 5% within an hour, losing fluorescence and destabilizing the metal-nitrosyl 
compound. The more acidic pH environments observed in live cells elicit greater loss 
(approximately 10%) of resorufin in live cell cultures over an hour, further limiting complex 
tracking for in vivo experiments.28 
 
Figure 1.2. Ruthenium centered PhotoNORMs. 
Porphyrins, commonly used for biological purposes in heme and oxygen 
transportation, was an ideal selection for a due to the presence of the ligand in biology where 
stability and water solubility are obviously not problematic. Unfortunately, porphyrin 
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ruthenium nitrosyls, while water soluble, have been shown to have a fast back reaction to 
reform the nitrosyl with a rate k < 107M-1s-1.29, 30 This rapid back reaction limits the application 
of this class of photoactive compounds as NO releasers, since the bound ruthenium-nitrosyl 
is too stable for the desired applications.  
Schiff base ligands however, formed from the condensation of an aldehyde and amine, 
are easily modifiable. Ruthenium nitrosyl salen and salophen compounds are oxygen, water, 
and thermally stable while retaining photolability of the metal-NO bond upon excitation with 
the appropriate wavelength for the metal to ligand charge transfer band (MLCT). The initial 
catalyst, Ru(NO)(salen)Cl was studied by Carmen F. Works.31 Dr. Works’ research showed 
the ability of the ruthenium nitrosyl to release NO at several excitation wavelengths with 
photochemical activity up to 546 nm with a QY of 7% in acetonitrile .31 Attempts to red-shift 
the absorbance have led to incorporation of salophen ligands, which afford an approximately 
100 nm bathochromic shift in absorbance maxima and afford visible light excitation for metal-
NO bond excitation. A representative example is the comparison of Ru(tBu4salen)(NO)Cl 
with Ru(tBu4salophen)(NO)Cl, where incorporation of the salophen ligand results in shift in 
maxima from 370 nm to 468 nm. Moreover, the quantum yield upon irradiation at 365 nm 
increasing from 0.030 for the salen complex to 0.055 for the salophen complex, with 
photoactivated NO release still being efficient for the salophen upon excitation at 546 nm ( 
= 0.011).31  
1.6 Up-Converting Nano Particles 
 Nanoparticles (NPs), as the name describes, are defined as particles with a diameter 
equal to or less than 100 nm.32 Presently, nanoparticles are being explored for a variety of 
purposes in medicinal chemistry, ranging from direct treatment to drug payload delivery.33, 34, 
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35, 36  In the context of photoactivated therapy, the photophysical properties of nanoparticles 
are most interesting, as interactions of light with certain nanoparticles can be employed to 
increase efficiency of photochemical processes at wavelengths were the photoactivated drug 
may not absorb light sufficiently. One process that is uniquely applicable is that of 
upconversion, when two or more photons of light are absorbed by a system and the resulting 
emitted wavelength of light is higher in energy than a single photon of absorbed light.37 This 
can occur by two different mechanisms: simultaneous absorption or sequential absorption. 
Simultaneous absorbance of two (or more) photons requires excitation by a pulse laser with a 
high power density (~106 W/cm2). 38 Sequential excitation however, involves long lived 
excited states that can absorb photons from a continuous wave (CW) lamp or LED to convert 
low energy light into high energy emission or higher energy anti-Stokes luminescence.38 
  The upconverting nanoparticles (UCNPs) used in the studies to follow undergo 
sequential absorbance in order to emit higher energy light. This is achieved when a photon of 
light is absorbed by a system, the excited state then undergoes intersystem crossing (isc) to an 
excited state with a long half-life.38 A second photon is then absorbed and the electron excited 
into a higher occupied state, and the UCNP eventually relaxes via emission of a single photon. 
Once the photon is emitted, the energy released is then greater (lower wavelength) than one 
photon absorbed (higher wavelength) and is referred to as a two-photon or multi photon 
UCNP.  
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Figure 1.3. Simplified depiction of two-photon absorbance and emission of a higher energy 
light. 
 UCNPs have been explored heavily for uses in biolabeling, optical storage, solid state 
lasers, light emitting diodes (LEDs), display systems, and imaging.39, 40 For bioimaging, the 
surface of particles is modified with PEG groups and can be circulated through a mouse 
system. The PEGylated particles collect within the tumor and low energy light is used to excite 
the UCNPs, where the emission is imaged and the tumor can be identified.33, 34 More recently, 
UCNPs have been imbedded within a micelle that contains a drug payload. Upon irradiation, 
the high energy emission causes the micelle to break and the drug is released at a specified 
location.35, 36 The work here will center on exploiting UCNPs for their use in drug delivery, 
particularly the encapsulation of the particles within close proximity of a photoNORM to 
produce NO release due solely to the emission from the UCNP and the absorbance of the 
photoNORM by trivial energy transfer. 
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1.7 Statement of Goals (research aims)  
Photoactive drug delivery of caged compounds has been of great interest over the past 
two decades. Much focus has centered on delivering drugs that possesses a high degree of 
specificity such that the drug does not activate before it reaches the target location. A 
secondary approach to specificity is to design a drug that is photoactive; a compound that can 
passively travel through the body while retaining activity once it reaches the desired location 
and can be triggered externally, in this case with light irradiation. The photochemical release 
at a biological target would enable defined concentrations of that drug to be delivered locally 
and diminish systemic side-effects associated with overdosing. This method will potentially 
allow a caged drug to be administered without consequence until the photolysis is directed to 
a specific location. Thus one is able to specify the location, timing, and dosage of such an 
event.41 In this context, we42 and others43 have been studying the photochemistry of ruthenium 
nitrosyl compounds owing to their thermal stability, low toxicity, and the photolability of the 
Ru-NO bond with light to release nitric oxide.  
Many current techniques of chemotherapy and anti-cancer treatments have extremely 
negative side effects, such as nausea, anemia, blood disorders, nerve damage, and irreversible 
damage to internal organs such as the heart and liver.44 Consequently, research is ongoing to 
develop better drug delivery methods and drugs with greater specificity and leaving healthy 
cells unharmed. Due to the wide variety of roles that NO can play, it is extremely important 
to control the concentration released in any therapeutic application.45 With such 
considerations, there are continuing efforts to make photoactive nitric oxide donors with high 
biological stability,46, 47, 48, 49 , 50 and ruthenium nitrosyls are of particular interest owing to the 
photolability of the otherwise very stable Ru-NO bond.  
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Traditional drug delivery methods consist primarily of oral delivery, intravenous 
delivery, inhalation or topical application of drugs. Probably the most coming drug delivery 
method, oral delivery consists of simply swallowing the drug followed by uptake to the 
bloodstream in the intestine and systemic transport as opposed to specific regionalization.51 If 
the drug is intended for use past the stomach, the pills are coated with sodium alginate, calcium 
chloride, or various polymers to survive the stomach acid.51 Inhalation therapy is utilized for 
the administration of lung specific drugs through aerosol sprays such as asthma inhalers and 
topical creams such as steroids, are absorbed through the skin at the intended site.51 
Intravenous drug delivery is utilized heavily in hospitals and chemotherapy applications. 
Water solubility can limit IV delivery and therefore, water insoluble drugs are commonly 
dissolved in a DMSO/ water mixture, additionally drug uptake is highly concentrated at the 
lining of the endothelial cells.52 Drug specificity is controlled with targeting utilizing specific 
ligands, hormones, vitamins, growth factors, or peptides.51 However, the release and uptake 
of drugs is highly dependent on an individual’s metabolic systems and release of the active 
pharmacokinetic drug is often non-specific.  
In this context, we have prepared several ruthenium nitrosyl compounds that will be 
discussed over the next several chapters. Each of these compounds are water, oxygen, and 
thermally stable while retaining the photolability of NO release. Each compound has been 
characterized by NMR, IR, UV-visible spectra, mass spectroscopy, and their ability to release 
nitric oxide upon photolysis (quantum yield). I also report the activity of Ru(NO)(salen-
CO2H)Cl (1) (salen-CO2H = N,N'-ethylenebis(3,3’-bis-carboxyl-salicylidene-iminato) in cell 
toxicity and vascular reactivity studies.   
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To limit the potential toxicity, we will also discuss encapsulation of the pro-drug, 
Ru(NO)(salophen)Cl, into biocompatible polymers poly(lactic-co-glycolic acid) (PLGA) and 
Polydimethylsiloxane (PDMS). These polymers are FDA approved for biological use and 
have been greatly studied.53, 54 Additionally, PLGA and PDMS are both hydrophobic and can 
be synthesized to encapsulate both hydrophobic UCNPs and photoNORMs concurrently, 
therefore these matrices have the ability to induce NO release from near infra-red photolysis 
(falling within the therapeutic window of 700-1100 nm15). 
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Chapter 2. Experimental Section 
2.1 Reagents, Solvents, and Gases 
2.1.1. Reagents 
Ruthenium(III) nitrosyl chloride mono hydrate was purchased from Strem Chemicals 
Inc. Remaining synthetic materials including trifluoroacetic acid, 4-hydroxybenzoic, 
hexamethylenetetramine, and laboratory solvents were purchased from Sigma-Aldrich. 95% 
sodium hydride was purchased from Sigma-Aldrich and store in an inert glove box and 
transferred into an inert reaction flask for use on the Schlenk line. Actinometry solvents were 
prepared according to the Calvert and Pitts1 and potassium ferrioxalate was purchased from 
Strem Chemicals. 
2.1.2. Cell media  
Cell lines, media, and MTT assay reagents for cell toxicity studies were provided by 
the Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo.   
2.1.3. Solvents 
Solvents were purchased from Fisher Scientific. THF was distilled and stored in the 
glove box. Deuterated solvents for NMR were purchased from Cambridge Isotope 
Laboratories. All buffers used for quantum yield and fluorescent measurements were prepared 
in nanopure water at 50 mM concentrations. The exact pH was adjusted using dilute NaOH 
or HCl as required. Phosphate buffers were prepared for pH values 11.0, 7.4, 6.0, and 4.5 
while a HCl/KCl buffer was used for pH 1.0 and tris(hydroxymethyl)aminomethane ("Tris") 
was used to prepare the pH 9.0 buffer. Standard Krebs buffer (mM): NaCl (130.0), KCl (4.7), 
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KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (14.9), glucose (5.5) and CaCl2 (1.6) was made with 
sterile deionized water.  
2.1.4. Gases 
Argon for reactions under an inert atmosphere was purchased from Praxair and passed 
through a desiccant column to remove gaseous water before introducing to the reaction flask. 
Medical grade air and helium were purchased from Praxair and used on the Nitric Oxide 
Analyzer as carrier gasses.  
2.1.5. Instruments 
NMR spectra were collected on a 400 or 500 mHz Varian NMR. Absorbance spectra 
were taken on a Shimadzu UV-2401PC UV-visible spectrophotomer or a Stellar Net SL5-DH 
spectrophotometer over the wavelength range 800nm to 200 nm. Fluorescence and emission 
data were collected on a Photon Technology International fluorimeter with a model 814 PMT 
detection system at 1 nm resolution with an Ushio Xenon arc lamp and Hammamatsu R928P 
PMT. Infra-red spectra were recorded on a Mattson Research Series FTIR or a PerkinElmer 
UATR Two spectrometer. Nitric oxide production was monitored on a General Electric 
Sievers Nitric Oxide Analyzer NOA 1080i (NOA). Samples were irradiated by either a high-
pressure Oriel Hg lamp with 365 nm interference filters or by a Lexion LED (470 nm) as 
specified.   
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2.2  Ligand Synthesis 
2.2.1 Salicylaldehyde-4-carboxylic acid 
 The salicylaldehyde-4-carboxylic acid was synthesized according to published 
procedures2  and is outlined in Scheme 1. An overview is detailed here: 4-hydroxybenzoic 
acid (15.0 g, 36.2 mmol) was dissolved in 30 mL triflouroacetic acid under argon atmosphere. 
A solution of hexamethylenetetramine (15.3 g, 36.4 mmol) dissolved in 48 mL of 
triflouroacetic acid was added drop-wise to the 4-hydroxybenzoic acid with rapid stirring over 
40 minutes. The resulting mixture was then refluxed with rapid stirring under an inert 
atmosphere. Thin layer chromatography (TLC) was used to monitor the rate of the reaction 
with a chloroform: methanol 100:15 mobile phase. The solution was allowed to reflux for 4 h 
or until the 4-hydroxybenzoic acid was no longer observed by TLC.  
The reaction mixture was removed from heat and allowed to cool to room temperature 
after which it was transferred into a flask containing 300 mL of aqueous 4 M HCl and stirred 
at room temperature for 3 h in the presence of air. The resulting yellow precipitate was filtered 
in air and washed with approximately 200 mL of nanopure water. Crude solid was 
recrystallized from ethanol, filtered and washed with cold ethanol and allowed to dry fully 
under vacuum. The product was confirmed by 1H NMR in accordance to published work. 1H 
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NMR (CD3OD, 500 MHz): δ 10.15 (1H, s, HC=O), 8.44 (1H, d), 8.20 (1H, dd), 7.06 (1H, d) 
phenyl protons (Figure 1). 
 
Scheme 1. Synthesis of salicylaldehyde-4-carboxylic acid according to published 
proceedures.2 
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Figure 4. 1H NMR spectra of salicylaldehyde-4-carboxylic acid in deuterated methanol at 
room temperature.  
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2.2.2 Salen-CO2H 
The carboxylic acid derivative of the salen ligand (3,3'-((1E,1'E)-(ethane-1,2-
diylbis(azanylylidene))bis(methanylylidene))bis(4-hydroxybenzoic acid)) or "salen-CO2H" 
was prepared according to the reaction sequence outlined in Scheme 2. The salen-CO2H was 
synthesized by the condensation of salicylaldehyde-4-carboxylic acid with ethylenediamine. 
Briefly, salicylaldehyde-4-carboxylic acid (1.79 g, 10.8 mmol, 2 eq.) was dissolved in 15 mL 
of ethanol with mild heating and stirring. A solution of ethylenediamine (0.324 g, 5.39 mmol, 
1 eq.) in 10 mL of ethanol was added to the salicylaldehyde solution causing an immediate 
formation of precipitates. The reaction was allowed to run to completion by heating at reflux 
for 1 h with stirring. The solution was removed from heat and the solid was allowed to 
precipitate. The yellow precipitate was collected by filtration, washed with cold ethanol and 
dried under vacuum. (Scheme 2) 1H NMR (D2O, 500 MHz):  δ: 8.71 (1H, s) methane protons, 
8.04 (1H, d), 7.84 (1H, d), 6.87 (1H, d) phenyl protons, 3.95 (2H, s) ethylene bridge (Figure 
2). MS(FAB+): m/z 353.05 (M -3 H+). Elemental Analysis C 57.80%, H 4.20%, N 7.90%. 
Theoretical C 60.67%, H 4.53%, N 7.86%. 
 
Scheme 2. Synthetic scheme of the condensation reaction to produce the carboxylic acid 
modified salen, salen-CO2H.  
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Figure 5. 1H NMR spectra of salen-CO2H in (CD3)2SO at room temperature. 
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2.2.3 Salophen 
 Reagents to synthesize the salophen ligand were commercially available and used 
without further purification. Salicylaldehyde (2.10 mL of 19.8 mmoles, 2 eq.) was dissolved 
in approximately 100 mL of ethanol and heated with stirring (Scheme 3). To the hot solution, 
one equivalent of 1,2-phenylene diamine (1.0658 g, 9.86 mmoles.) was added and the solution 
was heated at reflux for 2 hours. The mixture containing this yellow precipitate was allowed 
to cool slowly and precipitate from the solution. Once at room temperature the solid was 
filtered and washed with cold ethanol to produce 2.5652 g of product. The 1H NMR spectrum 
in acetonitrile (CD3CN, 500 MHz) gave the following resonances:  δ: 8.78 (2H, s) imine 
protons, 7.53 (2H, d), 7.40 (6H, m), 6.98 (4, d) phenyl protons (Figures 3 and 4). Elemental 
Analysis C 75.8%, H 4.70%, N 8.40%. Theoretical C 75.93%, H 5.10%, N 8.86%. 
 
Scheme 3. Synthetic scheme of the condensation reaction to produce the salophen ligand. 
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Figure 6. 1H NMR spectra of the salophen ligand in deuterated acetonitrile at room 
temperature. 
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Figure 7. 1H NMR spectra of the salophen ligand in deuterated acetonitrile at room 
temperature. Aromatic splitting pattern is highlighted.  
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2.3 Synthesis of Ruthenium Nitrosyls 
2.3.1 Ru(NO)(salen-CO2H)Cl 
The nitrosyl complex chloridonitrosyl(N,N′-ethylenebis(3,3’-bis-
carboxylsalicylidene-iminato)ruthenium(III), Ru(salenCO2H)(NO)Cl (1) was prepared as 
follows.  A mixture of salen-CO2H (0.50 g, 1.41 mmol), sodium hydride (0.107 g, 4.45 mmol), 
and trichloridonitrosylruthenium(III) monohydrate, Ru(NO)Cl3•H2O, (0.317 g, 1.41 mmol) 
was added to a three neck 300 mL round bottom flask and placed under an argon atmosphere.  
Approximately 150 mL of deaerated ethanol was then transferred via cannula into the reaction 
flask. The resulting solution was then refluxed under argon in the dark for 4 h, after which the 
reaction solution was allowed to cool to room temperature and the ethanol was removed via 
rotary evaporation. The sodium chloride byproduct was removed from the desired product by 
washing the solid with water adjusted to pH 5 with dilute HCl. The remaining solid was dried 
under vacuum for several h (Scheme 4, step iii). 1H NMR (DMSO-d6):  δ 8.69ppm (1H, s) 
methane protons, 8.02 (1H, s), 7.85 (1H, d), 6.83 (1H, d) phenyl protons, 3.94 (2H, s) ethylene 
bridge. Elemental Analysis C 37.04%, H 4.20%, N 7.98%. Theoretical [Ru(NO)(salen-CO2H, 
CO2Na)Cl•2H2O], C 37.35%, H 2.96%, N 7.26%. (Figure 5). MS(FAB+): m/z 535.05 (M – 
NO+). FTIR (KBr) NO = 1865 cm-1. UV-vis (pH 7.4 50 mM phosphate buffer) max 248nm ( 
= 3.8 x 104 M-1 s-1), 359 ( = 6.6 x 103 M-1 s-1).  
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Scheme 4. Complete synthesis of Ru(salen-CO2H)(NO)Cl: (i) triflouroacetic acid, under 
argon atmosphere, 4 h reflux; (ii)  0.5 equivalents of ethylenediamine refluxed in ethanol for 
1 h; (iii) 2.3 equiv. NaH, 1 equiv. Ru(NO)Cl3 • H2O, under argon, refluxed in ethanol for 4 h. 
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Figure 8. 1H NMR spectra of the Ru(NO)(salen-CO2H)Cl in d6 DMSO at room temperature. 
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2.3.2 Ru(NO)(salophen)Cl 
 Salophen (0.0647g, 0.205 mmol, 1 eq.) and NaH (0.0083g, 0.35 mmol, 1.5 eq.) were 
combined in 20 mL of distilled THF and put under argon. The evolution of hydrogen gas was 
immediately observed once the solvent was added. The reaction was allowed to continue for 
10 minutes with slight heating and stirring. 
 In the dark, RuCl3(NO)∙H2O (0.0522g, 0.204 mmol, 1 eq.) was dissolved in ~15 mL 
of THF under argon and then cannula-transferred into the salophen reaction flask.  The 
complete solution was refluxed under argon for 4 h before the solvent was removed by 
negative pressure (Scheme 5). 
 The product was chromatographed on a silica column with 99:1 chloroform: methanol 
to remove the excess ligand. The ratio was increased up to 3% methanol to remove the brown 
ruthenium band, which was collected and the sample was checked by 1H NMR in acetonitrile. 
1H NMR (CD3CN):  δ 8.63ppm (1H, s) methane protons, 7.54 (1H, m), 7.36 (2H, m), 7.23 
(1H, m), 7.02 (1H, m), 6.91 (1H, td) phenyl protons (Figures 6-8). Elemental Analysis C 
51.3%, H 3.36 %, N 8.86 %. Theoretical [Ru(NO)(salophen)Cl], C 49.96%, H 2.93%, N 
8.74%. MS(FAB+): m/z 504.03 (M + Na+) (Figure 9). FTIR (KBr) NO = 1882 cm-1. UV-vis 
(toluene) max 336 nm ( = 1.0 x 104 M-1 s-1), 465 ( = 2.7 x 103 M-1 s-1), (acetonitrile) max 
330 nm ( = 2.1 x 104 M-1 s-1), 440 ( = 5.2 x 103 M-1 s-1), (isopropyl acetate) max 330 nm ( 
= 1.7 x 104 M-1 s-1), 450 ( = 4.6 x 103 M-1 s-1). 
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Scheme 5. Insertion of the ruthenium nitrosyl into the ligand structure.  
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Figure 9. 1H NMR spectra of the Ru(NO)(salophen)Cl in CDCl3 at room temperature. Full 
spectra. 
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Figure 10. 1H NMR spectra of the Ru(NO)(salophen)Cl in CDCl3 at room temperature. 
Relevant peaks highlighted. 
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Figure 11. 1H NMR spectra of the Ru(NO)(salophen)Cl in CDCl3 at room temperature. 
Aromatic region highlighted. 
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Figure 12. Mass spectra, ESI+ for Ru(NO)(salophen)Cl + Na+  MW= 480.978 + 23 
2.4 Quantum yield measurements   
 39 
Quantum yields of NO release NO were measured using a GE model NOA 280i 
Sievers Nitric Oxide Analyzer (NOA), which quantitatively measures the NO present in a gas 
that has been entrained through the photolysis solution.3   The carrier gas is either helium or 
medical grade breathing air. This was first passed through a glass chamber containing only 
the solvent solution prior to entering the reaction cell in order to prevent evaporative solvent 
loss and to maintain a constant volume in the reaction cell throughout the experiment. The 
solvent saturated carrier gas was then run through a four sided, quartz cuvette (Y-cell) 
containing the photolysis solution to actively purge any NO generated.  This gas was then 
analyzed by the NOA for its NO content. Unless otherwise noted, experiments contained 3 
mL of reaction solution. The peak area was calculated using the software "Liquid", and the 
moles of NO were calculated based on the calibration curve. Quantum yields were calculated 
by plotting the moles of NO released by the Einsteins of light absorbed during each exposure.   
Quantum yield measurements at the pH values at 1.0, 4.5, 6.0, 7.4, 9.0, and 11.0 were 
conducted individually using a stock solution of compound 1. The cuvette was filled with 3 
mL of pH adjusted solutions of 1 and entrained with carrier gas for 5 minutes, in order to 
allow the NOA establish a stable baseline. The photolysis was conducted at irr 365 nm with 
the light from a high pressure mercury lamp passed through a narrow band pass interference 
filter or at 470 nm with a blue LED from Luxeon. The intensity of the excitation at 365 nm 
was determined using ferrioxolate actinometry;1 and intensity of the LED light was measured 
with a Newport power meter. Individual samples were irradiated for varied time intervals 
controlled by a Uniblitz shutter, and the photchemically released NO was recorded using the 
NOA software, Liquid. The plotted slope is NO, therefore a slope of y = 0.0036x + 4E-11 
results in NO = 0.0036 or 0.36%. 
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2.4.1 Quantum Yield Calculations 
 The moles of photons of light absorbed by a reaction for quantum yield measurements 
requires the photons of light produced from the light source to be calculated. The photons 
absorbed by the sample are calculated by using the absorbance at the wavelength of 
irradiation. These are laid out in equations 1 and 2 where Io is equal to the incident light 
(photon flux) of the light source and I is equal to the photons transmitted through the sample. 
The incident light (Io) is subtracted by ten raised to the negative absorbance of the solution at 
the wavelength of irradiation. The light absorbed by the sample (Ia) therefore is equal to the 
moles of photons of light absorbed by the sample determined by subtracting transmitted light 
from incident light.  
 
Equation 1.  
 
Equation 2. 
 
 The moles of incident light are determined experimentally by either chemical 
actinometry or by a power meter measurements. Ferrioxolate actinometry has been the gold 
standard of actinometry for the wavelengths of 366, 405, 436, 468, 509, 546 nm,1 for other 
wavelengths a power meter has been used in this work.  
2.4.1.1 Calculations for Ferrioxolate Actinometry 
The procedure for ferrioxolate actinometry is written in Calvert and Pitts1; the 
calculations are described below.1 Potassium ferrioxolate has a well-defined quantum yield of 
photo reduction to Fe2+ in light when expose to 1,10-phenanthroline after photolysis. The 
I = I
o
 – 10
-Abs
 
I
a
 = I
o
 – I 
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moles of Fe2+ are calculated in Eq. 3 from the spectral difference of the actinometry solution 
at 510 nm after photolysis compared to a non-irradiated sample. Following the procedure laid 
out in Calvert and Pitts, vol. FeOx irr = volume of the irradiated sample (0.003 L), vol. FeOx 
used = volume of the irradiated sample aliquot used (0.002 L), Δ Abs = the change in 
absorbance at 510 nm between the irradiated and blank samples.   The incident light in photons 
per second (Np) is calculated from the moles of Fe
2+ (Eq. 4), using the known quantum yield 
at the irradiation wavelength (Φirr) of the reaction, the duration of irradiation (t) resulting in 
photons per second, and Ia which is calculated with the absorbance of the ferrioxolate solution 
at the irradiation wavelength (Ia = 1- 10
-Abs). The final incident light is converted to moles of 
photons per second (known as Einsteins) by dividing Np by Avogadro’s number (Equation 5). 
Incident light (Io) from Eq. 5 is used in equations 1 and 2 to calculate the quantum yield of an 
unknown compound.  
 
      Equation 3.  
 
Equation 4.  
 
Equation 5.  
2.4.1.2 Calculations for Power Meter Measurements 
 A power meter was also used in these studies to find Io for wavelengths not covered 
by ferrioxolate actinometry. Power meters such as the Newport power meter used in these 
experiments, give a power reading in units of Watts with a range from W to nW scale. To 
convert watts to moles of photons of light absorbed, the number of photons must first be 
Moles Fe
2+
 = ( 
(6.022E23)(𝑣𝑜𝑙. 𝐹𝑒𝑂𝑥 𝑖𝑟𝑟)(𝑣𝑜𝑙.  𝐹𝑒𝑂𝑥 𝑢𝑠𝑒𝑑)(𝛥 𝐴𝑏𝑠.)
(𝑣𝑜𝑙.  𝐹𝑒𝑂𝑥 𝑢𝑠𝑒𝑑)(𝑏)(𝜀)
 ) 
N
p
  = ( 
𝑚𝑜𝑙𝑒𝑠 𝐹𝑒2+
(Φ𝑖𝑟𝑟)(𝑡)(Ia)
 ) 
I
o
  = ( 
Np/s
(6.022𝐸23)
 ) 
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calculated. The number of photons (Np, Eq. 6) is calculated from watts measured (E) and 
energy quanta of the wavelength of light (Ep). The energy quanta is calculated by multiplying 
Plancks constant (h = 6.63E-34 J•s) with the frequency (f), the frequency is the product of the 
speed of light (c = 2.988E-8 m/s2) divided by the irradiation wavelength in meters (λ) (Eq. 7).  
To convert into photon flux, Np is divided by Avogadro’s number which results in the photon 
flux in Einsteins.  
 
Equation 6.  
 
Equation 7.  
 
Equation 8.  
 
2.5 pKa measurements 
Shifts in UV-visible spectrum of 1 as the pH was changed are indicative of the 
functioning of several acid/base dependent equilibria for this compound. In order to determine 
these quantitatively, compound 1 was dissolved in slightly basic water and diluted to a 
concentration of 0.15 mM in 50 mM KCl solution. The pH was adjusted with slow addition 
of dilute hydrochloric acid and determined with a pH meter. The pH was allowed to stabilize 
each time before the UV-visible spectrum was recorded. 
N
p
  = ( 
𝐸
𝐸p
 ) 
I
o
  = ( 
Np
(6.022𝐸23)
 ) 
E
p
  = h • f = ( h 
𝑐
𝜆
 ) 
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2.6 Cell viability studies  
Murine melanoma B16F10 cells were grown (2 × 105 cells/well), incubated, and plated 
in 96-well plates according to published procedures4. Each well contained 200 L of Roswell 
Park Memorial Institute 1640 medium (RPMI) enriched with 2% Fetal Bovine Serum (FBS).  
Stock solutions of 1 were prepared in concentrations of 20 mM, 10 mM, 2 mM, and 1 mM, 
and 2 L aliquots of these solutions were added to individual wells to establish different 
concentrations. The final concentrations of 1 in the wells were 200 M, 100 M, 20 M, 10 
M, and 0 M (control).  The cells were incubated with 1 in the dark for 4 h. After incubation 
the media containing 1 was removed and replaced with fresh media before exposure to light. 
Phenol red indicator was not used in the media during the photolysis to avoid light being 
absorbed by the indicator. Half of the cell plates were irradiated with 470 nm light for 4 min 
with a modified cell plate LED. All plates were then incubated for either 24 or 48 h.  
 Cell viability was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
ditetrazolium bromide) assay protocol.4 After 24 or 48 h, the media was removed and 200 L 
MTT solution (5mg/mL phosphate buffer) was added to each well. The plates were incubated 
with the MTT for 3 h before the solution was removed and replaced with 200 L of DMSO. 
(MTT solution; 12 mM thiazolyl blue tetrazolium bromide in phosphate buffer was diluted in 
media to a final concentration of 1.2 mM.) The plates were left in the dark for 18 h, and their 
absorbance was recorded by a Thermo Plate leitora de microplaca TP-reader plate reader at 
492 nm.  The reported values are an average of two weeks of cell studies equating to 4 plates 
for each time point. Each plate had 8 samples of the same concentration under identical 
conditions.  Viability was determined based on the results of the MTT assay. The data was 
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normalized to the control wells in each plate not containing compound 1. Data was compiled 
and processed using Prism 3.0 software. 
2.7 Vascular dilation studies  
Male rats (180-200 g) were sacrificed by decapitation under anesthesia. The thoracic 
aorta was quickly removed, and cut into rings (4-5 mm length). The endothelium was 
mechanically removed from one of the two rings by gently rolling the lumen of the vessel on 
a thin wire. Aortic rings with and without endothelium cells were studied concurrently. The 
aortic rings were placed between two stainless-steel stirrups and connected to an isometric 
force transducer (Letica Scientific Instruments, Barcelona–Spain) to measure tension in the 
vessels. The rings were placed in an organ chamber containing Krebs solution with the 
following composition (mM): NaCl (130.0), KCl (4.7), KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 
(14.9), glucose (5.5) and CaCl2 (1.6). The solution was maintained at pH 7.4 and bubbled with 
a gas mixture of 95% O2 and 5% CO2 at 37 °C. The rings were initially stretched to a basal 
tension of 1.5 g and allowed to equilibrate for 60 min. The presence of endothelium was 
evaluated by the degree of relaxation induced by acetylcholine (1 µM) in the presence of 
contractile tone first induced by phenylephrine (PE, 0.1 µM). Endothelium-intact arteries were 
discarded if relaxation with acetylcholine was not greater than 80% while endothelium-
denuded arteries were discarded if there was degree of relaxation for acetylcholine higher than 
10%. The comparisons between groups were assessed by student t- test. The level of statistical 
significance was defined as P<0.05. 
 The rings were returned to the basal tension of 1.5 g with 10 L of PE (0.1 M) and 
allowed to stabilize for 10 minutes prior to the injection of 1 and two tests for induced 
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relaxation were conducted, the incremental increase of 1 and the time course relaxation with 
a high concentration of 1.  
Stock solutions of 1 at  concentrations from 0.1 M - 5 mM were prepared and injected 
in sequence to the Krebs buffered organ chambers.  The final concentrations ranged of 10-10 
M up to 10-4 M. Tension levels were allowed to stabilize prior to the addition of a higher 
concentration of 1 (Figure 4). The time course for 1-induced relaxation was monitored over 
the course of an hour following the single injection of 20 L of 5 mM 1 for a finial 
concentration of 10-5 M. (Figure 5). Experiments were conducted in either the dark or in 
ambient light. 
2.8 NOA Calibration 
 Calibration curves for the NOA were run once a month to ensure accuracy. Stock 
solutions of sodium nitrite in nanopure water were prepared in serial dilution ranging from 1 
M to 100 M. The stock solution was injected in triplicate at 5 L resulting in a calibration 
curve ranging from a total of 5 pmoles to 500 pmoles. A standard operating procedure (SOP) 
is listed in Appendix 1.  
The NOA was calibrated per the manufacturer's specifications.5  Briefly, the reaction 
cell was prepared by dissolving KI (50 mg) into 2 mL of nanopure water and 4 mL of glacial 
acetic acid. Helium was bubbled through the cell until a baseline below 10 mV was reached. 
Nitric oxide was generated in the cell by injecting 5 L aliquots of increasing concentrations 
of NaNO2 in nanopure water through a septum. The PMT response of the NOA was allowed 
to return to baseline before the next injection. The integrated signal was used to create a 
calibration curve. 
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2.9 UCNP experimental Synthesis of NaYF4: Yb30Gd20Tm0.2 @ NaYF4 
 UCNPs used in this experiment were synthesized at the Molecular Foundry in 
Berkeley, Ca. using the automated robotic system WANDA (Workstation for Automated 
Nanomaterial Discovery and Analysis). The highly precise reaction conditions that WANDA 
is able to control on individual reactors allows for high reproducibility in nanoparticle 
synthesis. Synthesis data described in the work of P. T. Burks, et. al.6 
2.10 PLGA Nanoparticles 
 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles with hydrophobic UCNPs and 
PhotoNORMs, Yb30Gd20Tm0.2 @ NaYF4 and Ru(NO)(salophen)Cl (2) were synthesized and 
characterized by Dr. Agustin Pierri and Po-Ju Huang.7 
2.11 PDMS Polymer Disks 
2.11.1 Synthesis of PDMS Polymer Disks 
 Polymer disks were prepared working with Dr. John Garcia according to 
manufacturer’s specifications for SYLGARD 184. The polydimethylsiloxane (PDMS) liquid 
was mixed with the curing agent (Catalyst 87-RC) in a 10:1 ratio and thoroughly mixed. The 
mixture was put under reduced pressure for 30 minutes to remove oxygen and bubbles that 
had formed during mixing. A Teflon mold was then filled with the viscous polymer solution 
and was allowed to cure at room temperature for 36 hours until solid.  
2.11.2 Loading Up-converting Nanoparticles into PDs 
 The PDMS disks with up-converting nano particles (UCNPs) were prepared in the 
same manner as the blank PDs. However, the molds were filled half way with the PDMS and 
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then 2 mg, 5 mg, or 8 mg of Yb30Gd20Tm0.2 @ NaYF4 UCNPs were added. The UCNPs were 
stirred into the viscous polymer and additional polymer was added to fill the mold. UCNP 
loaded PDs were left to cure at room temperature for 36 hours.  
2.11.3 Infusing Ru(NO)(salophen)Cl into PDs 
 The hydrophobic complex Ru(NO)(salophen)Cl was infused into the PDMS polymers 
in the dark under ambient conditions. A concentrated solution of Ru(NO)(salophen)Cl was 
prepared in THF. One 1 cm diameter polymer disk was suspended in 2 mL of the stock 
solution for 5 minutes. The solvent was slowly removed over the course of 2 hours under 
negative pressure. The cycle was repeated three times for each polymer disk, suspending the 
polymer in an additional 2 mL of stock solution and allowing the sample to rest before the 
slow concentration of the solution and removal of the solvent.  
 The samples were washed with nanopure water until UV-visible spectra showed no 
ruthenium leeching from the polymer. The samples were stored under vacuum.  
2.11.4 Efficiency of NO release experiments 
 The loaded polymer disks (PDs) were attached to a glass coverslip with clear, double 
side adhesive strips. The glass coverslip was loaded into the flow cell chamber (custom built 
for the related study by Burks et. al.6), which has an input valve and an output valve to flow 
carrier gas through the dry chamber and into the Sievers Nitric Oxide Analyzer for accurate 
NO release data. The samples were irradiated with a 980 nm multimodal diode laser and 
exposure time was controlled using a Uniblitz shutter.  
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Chapter 3. Physical and Spectral Properties of Ru(NO)(Salen-CO2H)Cl  
3.1 Introduction 
 Ruthenium salen species have been studies for the past several years for their ability 
to release NO when irradiated with light.1 Previous studies with ruthenium salen derivatives 
have involved complexes that are photoactive when irradiated in the near-ultra violet spectral 
region but have poor water solubility. Described here is the synthesis of a carboxylated salen 
complex Ru(NO)(Salen-CO2H)Cl (salen-CO2H = 3,3'-((1E,1'E)-(ethane-1,2-
diylbis(azanylylidene))bis(methanylylidene))bis(4-hydroxybenzoic acid)) that should have 
markedly improved water solubility, at least at pH values higher than the pKa of the pendant 
carboxylates. This compound was further studied to evaluate its solubility, photochemical 
reactivity, oxygen stability, and fluorescent properties. The synthetic procedure leading to this 
functionalized ruthenium salen nitrosyl complex Ru(salen-CO2H)(NO)Cl (1) is outlined in 
Scheme 3.1. Details are presented in the Experimental section (sec 1.2 – 1.3.1). 
Scheme 3.1. Synthesis of Ru(salen-CO2H)(NO)Cl: (i) triflouroacetic acid, 4 h reflux under 
argon; (ii) Ethylenediamine (0.5 equiv.), EtOH, reflux 1 h; (iii) NaH (2.3 equiv.), Ru(NO)Cl3 
• H2O (1 equiv.), EtOH, 4 h reflux under argon.  
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3.2 pH Dependent Spectroscopic Properties 
 The optical absorption spectrum of compound 1 displays considerable pH dependence. 
For example, the band maxima (λmax) for both the visible and UV peaks (Figure 3.1) vary with 
changing pH. These spectral shifts can be attributed to three acid/base dependent reactions: 
the nitrosyl (NO) to nitrite (NO2) conversion and the deprotonation/protonation of both ligand 
carboxylates (Scheme 3.2). Ruthenium based nitrosyl to nitrite conversions have been studied 
by Tfouni and coworkers2, 3 and others.4   
 
Scheme 3.2. pH dependence of compound 1: i.) nitrosyl to nitrite conversion at a pH greater 
than 7.65 and ii.) deprotonation of one carboxylic acid 
 
Figure 3.1. pH dependent spectra of Ru(salen-CO2H)(NO)Cl (1) in 50 mM phosphate solution 
titrated to a pH of 1.0, 7.04, and 11.07. At pH 7.4, absorbance maxima are at 248 nm ( = 3.8 
x 104 M-1 s-1) and 359 nm ( = 6.6 x 103 M-1 s-1 ). 
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3.2.1 pKa characterization 
 A 0.3 mM solution of 1 was prepared in nanopure water containing 10 mM sodium 
chloride. The solution was adjusted to a pH of 11.5 with NaOH and allowed to equilibrate for 
1 minute to establish a stable solution pH prior to titration. At this pH both carboxylate groups 
should be deprotonated (example: terephthalic acid pKa1 = 3.52, pKa2 = 4.46
5) and the nitrite 
species should be prevalent over the nitrosyl species.6, 7 The solution was then titrated slowly 
with HCl and the UV-visible spectra was recorded at each interval to identify the 
spectroscopic shift due to pH. Over the pH range from 11.5 to 0.5, 100 separate pH dependent 
spectral data points were collected. The dilution of the samples were normalized based on 
isosbestic points at 323 nm and 438 nm were identified by preparing phosphate buffered 
solutions at different pH values from a stock solution of 30 μM of 1. 
 The separate pKa values can be identified by specific decreases in absorbance at 371 
nm, 323 nm, and 247 nm. The pKa of the nitrosyl/nitrite reduction was identified by plotting 
the ratio of the absorbance at 371 nm to that at 323 nm (Abs371/Abs323) over the pH range 3.5 
to 11.5 (Figure 3.2). The observed inflection point at pH 7.65 is consistent with known pKa 
values of the nitrosyl/nitrite conversion (Scheme 3.2, eq. i). The nitrosyl ligand undergoes 
nucleophilic attack by hydroxide resulting in a ruthenium coordinated N-nitrito complex as 
observed in research by Tfouni and co-workers.6, 7, 8 The pH dependent NO+ to NO2
– 
conversion is further supported by observed spectral changes in the IR spectra where the 1865 
cm-1 nitrosyl peak disappears and nitrosyl peaks appear at 1427 and 878 cm-1 when dissolved 
in a sodium hydroxide solution. Upon the addition of hydrochloric acid, the nitrite peaks are 
no longer present and the nitrosyl peak returns at 1865 cm-1. 
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Figure 3.2. Ratio of the absorbance at 371 nm to the absorbance at 323 nm with varying pH. 
The inflection point (dashed line) represents the pKa of the nitrite to nitrosyl conversion at pH 
7.65. 
 
Figure 3.3. Ratio of the absorbance at 247 nm to the absorbance at 438 nm with varying pH. 
The inflection point (dashed line) represents the pKa of one (or both) of the carboxylate groups 
at pH 3.65.  
 Although pKa values were expected for each of the carboxylic acid/ carboxylate 
protonation at lower pH, only one was identified. The expected second pKa of the carboxylic 
acid was not spectrally observed in the pH titration, very likely because once the compound 
has reached the second pKa the compound will be neutral and lose its solubility in water. This 
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was observed once the pH of solution dropped below 1 and the compound would precipitate 
from solution. The pKa of the carboxylate/ carboxylic acid was determined by charting the 
appearance of a band at 247 nm with decreasing pH. To adjust for dilution, the ratio of 
absorbance change for 247 nm versus 428 nm was plotted against pH change where 428 nm 
is an isosbestic point. The Abs277/Abs428 ratio was plotted versus a pH from 0.5 to 6. A single 
inflection point was apparent at a pH of 3.65 which was attributed to the pKa of one or both 
carboxylic acid groups (Figure 3.3). 
 All pH dependent spectral changes were recovered when the solution was back titrated 
from acidic pH to a basic solution. The spectral reversibility suggests that the compound is 
stable at a wide range of pH values (pH 0.5-11) and does not decompose. The clear isosbestic 
points are also indicative of the nitrite compound converting to the nitrosyl followed by the 
protonation of the carboxylate. The compound is highly stable with reversible carboxylic acid 
and nitrosyl/ nitrite equilibria that are pH dependent (Scheme 3.2). 
3.3 Quantum yields 
The quantum yield of nitric oxide release from 1 (NO) was determined under a variety 
of conditions. These included changing the pH of solution, the presence or absence of oxygen, 
and the wavelength of the irradiation light.  
3.3.1 Quantum yields at pH 7.4, 6.0, and 4.5 
Quantum yields are the measure of moles of product divided by the number of photons 
of light absorbed by the compound undergoing photolysis. The generation of nitric oxide in 
these experiments was determined using a Sievers Nitric Oxide Analyzer (NOA) to directly 
measure the moles of NO produced under a specific set of conditions. The quantum yields 
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will be depicted as NO to designate the quantum yield of NO production upon photolysis of 
a photoNORM. In graphs used to display NO, the production of NO release is plotted on the 
y-axis versus the light absorbed in Einsteins on the x-axis, providing a slope equal to the NO.  
Experiments to determine the quantum yield of NO release were conducted in 50 mM 
buffered solutions at several pH values to examine effects of the dramatic shift in the 
absorbance spectra due to pH changes and establish any possible pH dependence on the 
ruthenium nitrosyl bond photolysis. Phosphate buffers were used at pH 11.0, 7.4, 6.0, and 4.5 
while an HCl/KCl buffer was used for pH 1.0. Tris(hydroxymethyl)aminomethane ("Tris") 
was used to prepare buffer at pH 9.0. Buffered samples within the biologically relevant pH 
range of 7.4 – 4.5 are of particular interest as hypoxic tumors and cancerous tissue can have 
an internal pH ranging from 6.8 – 4.5 whereas healthy tissue generally maintains a pH of 7.4.9 
Quantum yields in phosphate buffer with helium carrier gas exhibits a pH dependent NO with 
quantum yields of 0.0026 ± 0.0003, 0.0048 ± 0.0003 and 0.0052 ± 0.0002 for the respective 
pH values 7.4, 6.0 and 4.5 when irradiated at 365 nm (Figure 3.4, 3.5, 3.6, respectively). Under 
oxygenated conditions, with medical grade breathing air carrier gas, NO values of 0.0020 ± 
0.0001, 0.0022 ± 0.0001 and 0.0033 ± 0.0001 were obtained for the same sequence of pH 
values (Figure 3.7, 3.8, 3.9). Changing the excitation to 470 nm provides quantum yields with 
the same pH dependence, increasing NO release with decreasing pH. The NO values for pH 
7.4, 6.0, and 4.5 at this longer wavelength excitation are 0.00020 ± 0.00002, 0.00024 ± 
0.00001, and 0.00026 ± 0.00001 (Figure 3.10, 3.11, 3.12, respectfully). 
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3.3.1.1 Quantum Yield Charts with pH and oxygen dependence 
The charts below are collected data from triplicate runs to determine NO at varying 
pH values, under inert carrier gas (helium) or in aerated conditions, and with irradiation 
wavelengths at 365 nm or 470 nm. As the pH decreases and more of the nitrite is converted 
to nitrosyl, there is an increase in NO. The plots show the moles of NO produced as 
determined by the NOA verses the amount of light absorbed in Einsteins (Ia*t). (Ia is the 
intensity of the light absorbed in Einsteins per second, t is in seconds.)  
 
Figure 3.4. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 7.4 in 
phosphate buffer. Irradiated at 365 nm under helium carrier gas. 
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Figure 3.5. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 6.0 in 
phosphate buffer. Irradiated at 365 nm under helium carrier gas 
 
 
Figure 3.6. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 4.5 in 
phosphate buffer. Irradiated at 365 nm under helium carrier gas. 
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Figure 3.7. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 7.4 in 
phosphate buffer. Irradiated at 365 nm under medical grade air carrier gas. 
 
 
Figure 3.8. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 6.0 in 
phosphate buffer. Irradiated at 365 nm under medical grade air carrier gas. 
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Figure 3.9. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 4.5 in 
phosphate buffer. Irradiated at 365 nm under medical grade air carrier gas.  
 
 
Figure 3.10. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 7.4 in 
phosphate buffer. Irradiated at 470 nm under medical grade air carrier gas. 
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Figure 3.11. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 6.0 in 
phosphate buffer. Irradiated at 470 nm under medical grade air carrier gas. 
 
 
Figure 3.12. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 4.5 in 
phosphate buffer. Irradiated at 470 nm under medical grade air carrier gas.  
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Table 3.1. Percent abundance of 1 with an axial Nitrite versus Nitrosyl and carboxylate versus 
carboxylic acid at experimental pH values. 
  pH Nitrite 
Population 
Nitrosyl 
Population 
Carboxylate   
Population 
Carboxylic acid 
Population 
11.0 99.99956% .00044%   
9.0 95.7% 4.3%   
7.4 35.97% 64.03% 99.982% .018% 
6.0 2.2% 97.8% 99.56% 0.45% 
4.5 0.07% 99.93% 87.63% 12.37% 
1.0 .00002% 99.99998% 0.22% 99.78% 
Values established using the Henderson-Hasselbalch Equation [pH = pKa + log10 ([A-
]/[HA])]. 
3.3.2 Quantum yield Discussion 
The increase in NO at lower pH can be correlated to the pH dependent population of 
the axial nitrosyl group versus an axial nitrite group. The ratio of nitrite: nitrosyl at pH 7.4 is 
approximately 36:64 while the population of the nitrosyl sharply increases as the pH decreases 
to values below the nitrite/ nitrosyl pKa (Scheme 3.2 eq. i). At pH 6.0 the ratio has shifted to 
a ratio of 2:98 and at 4.5 almost all of the axial ligand has converted to the nitrosyl. There is 
a corresponding increase in NO supporting the view that the nitrosyl form is considerably 
more photoactive than is the corresponding nitrito complex. This equilibrium is shown in 
Scheme 3.2 and presented in table 3.1 along with the population of protonated and 
deprotonated carboxylic acid. Therefore, as the pH drops from 7.4 to 6.0 the percentage of the 
nitrosyl has increased from 64% to 98% while the NO increased more than 80% (from 0.0026 
± 0.0003 to 0.0048 ± 0.0003, helium carrier gas, λirr = 365 nm). As the pH decreases and the 
population of the nitrosyl increases, the release of NO becomes more favorable and the 
quantum yields increase. 
The introduction of oxygen into the system induces a sharp decrease in the NO 
quantum yield, which is exaggerated as the pH drops from 7.4 down to 4.5. The NO at 7.4 
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decreased by 25% compared to the oxygen free photolysis conditions while the NO decreased 
by 55% for samples at a pH of 6.0 and a drop in NO of 65% was observed at pH 4.5. The 
trend of increasing NO with decreasing pH is maintained even when oxygen is introduced. 
The NO values here are consistent with reported data for the  based on the formation of the 
photoproduct for the [Ru(salen)(H2O)(NO)]Cl when photolysed at 365 nm in water resulting 
with a NO of 0.005 ± .001.10 
3.3.3 Quantum Yields at Extreme pH values  
Extreme pH values were also studied to ascertain their effect on the production of NO. 
At pH 11.0 and 9.0 the nitrite: 1  is almost entirely in the nitrite form resulting in a low NO 
of 0.0009 ± 0.0002 and 0.0005 ± 0.0001 when irradiated at 365 nm in aerated conditions 
(Figures 3.13 and 3.14). Similarly when considering the impact of acidic pH on nitrosyl/nitrite 
equilibrium, the high population of nitrosyl at pH 1 results in a NO of 0.0024 ± 0.0002 (Figure 
3.15). As reported above, the NO at pH 4.5 in oxygen saturated solutions has a quantum yield 
of NO release of 0.0033 while at pH 1 the NO drops to 0.0024 (Scheme 3.2, eq. 2). 
The large difference between NO at pH 11.0 and 9.0 versus that at pH values below 
the nitrite/nitrosyl pKa (7.65) shows the unfavorable photogeneration of NO from nitrite and 
increased production of NO once the ratio of axial nitrosyl has increased. In contrast to the 
strong dependence of NO on the nitrosyl pKa the acidification of the carboxylates functions 
(pKa 3.65) appears to have little effect. 
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Figure 3.13. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 11.0 in 
phosphate buffer. Irradiated at 365 nm under medical grade air carrier gas. 
 
 
Figure 3.14. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 9.0 in Tris 
buffer. Irradiated at 365 nm under medical grade air carrier gas. 
 63 
 
 
Figure 3.15. Quantum Yield of NO release from Ru(salenCO2H)(NO)Cl at pH 1.0 in HCl/ 
KCl buffer. Irradiated at 365 nm under medical grade air carrier gas. 
3.4 Fluorescence Properties of Compound 1 
While extensive NO release experiments were performed, the low quantum yields of 
NO release indicated alternative relaxation pathways for the excited compound. Therefore, 
the fluorescence properties were also examined and are described below. 
3.4.1 Fluorescence Experimental Design 
 Emission and excitation samples were prepared from the same stock solution of 
Ru(NO)(salen-CO2H)Cl (45.5 mM in nanopure water with NaOH). Each of the 6 samples 
were prepared by adding 40 L of stock solution and separate buffers were added to bring the 
samples up to volume in 10 mL volumetric flasks. Phosphate buffers were prepared for pH 
values 11.0, 7.4, 6.0, and 4.5 while an HCl/KCl buffer was used for pH 1.0 and 
tris(hydroxymethyl)aminomethane was used to prepare the pH 9.0 buffer. 
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3.4.2 Experimental Fluorescence Properties 
 A stock solution of 1 (45.5 mM) was diluted into a total volume of 10 mL at each 
buffered pH value tested resulting in a final concentration of 182 M of compound 1 at each 
of the pH values listed above. Samples were excited with 355 nm light and the emission 
maximum was observed at 505 nm regardless of pH, with the brightest emission specifically 
observed at pH 7.4 (Figure 3.16). Emission was adjusted for Io to account for the change in 
absorbance due to differences in pH. The emission at pH 11.0 decreases 30% from the pH 7.4 
sample, while pH values 9.0 and 6.0 show 50% less emission than that of the pH 7.4 sample. 
Excitation of compound 1 at pH 4.5 displayed only limited fluorescence emission while the 
most acidic solution (pH 1) displaying essentially no emission. Therefore, the fluorescence 
emission spectra as well as the NO are both highly pH sensitive, with differences owing to 
the pKa values and the overall charge of the compound in varying pH environments.  
 
Figure 3.16. Fluorescence emission of compound 1 with a em at 505 nm. Concentration 182 
M of 1 in 50 mM buffered solutions at each indicated pH.  
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Figure 3.17. Excitation spectra monitoring at 495 nm emission while scanning from 260 nm 
to 460 nm. Starting from top to bottom, max = 277nm at pH 11.0, shifting to 280 nm at lower 
pH. The second band beginning at max = 375 nm with the plateau ending at 425 nm. 
 As evident by the excitation spectra (Figure 3.17), excitation at 280 nm and at 375 nm 
result in strong emission at 495 nm. This emission is stronger at higher pH values and greatly 
decreases with the protonation of the carboxyl groups and are heavily influenced by the 
nitrite/nitrosyl conversion. Therefore, at the lowest pH solutions (4.5 and 1.0) are less 
emissive at 495 nm. From pH 9 to pH 7.4 the nitrosyl: nitrite ratio changes from 100% nitrite 
to 56:44, NO: NO2 (ratio calculated from the Henderson-Hasselbalch equation). A second 
excitation wavelength is allowed once the pH drops below the nitrosyl pKa causing a spike in 
the excitation and broadening the excitation band. The excitation spectra therefore shows the 
highest emission at 495 nm when at pH 11.0. A 25% decrease in emission at a pH of 7.4, 
followed by 9.0 and 6.0. As the pH continues to decrease the aromatic carboxyl groups begin 
to heavily influence the fluorescence quantum yield. 11 At a pH of 4.5 the ratio of deprotonated 
0.E+00
1.E+04
2.E+04
3.E+04
4.E+04
5.E+04
260 310 360 410 460
C
o
u
n
ts
Wavelength (nm)
pH 1
pH 4.5
pH 6.0
pH 7.4
pH 9.0
pH 11.0
 66 
to protonated carboxylate ratio has decreased to 88:12 resulting in lower emission while at pH 
of 1.0 where the ratio is 0.2:99.8, no emission is observed when excited.  
 Parallels can be drawn between this compound and fluorescein. Fluorescein has 
multiple pKa values which translate into absorbance and emission spectrums being highly pH 
dependent. When the pH drops below the pKa for the phenol group the quantum yield of 
emission dramatically decreases.12 Fluorescein’s emission decreases as it moves from the 
dianionic to anionic to neutral and regains a portion of the emission once in the cationic state 
(xanthylium species).  
3.5 Conclusion 
 Here we have synthesized and characterized a novel water soluble photoNORM. 
Several pKa values were identified for the nitrosyl to nitrite conversion at 7.65 consistent with 
research on similar compounds, and a single carboxylic acid pKa at 3.65, while protonation of 
the second carboxylate is thought to occur at a pH that is not evident in aqueous solutions 
employed, possibly due to a loss of solubility.13 The defined pKas proved to be of great 
importance and impact both the quantum yields as well as emission and excitation of the 
species. The pH dependent NO proves that the NO is released from a nitrosyl ligand and not 
from the nitrite. As the pH decreases, the alternative modes of energy release through 
fluorescence decrease and improve the release of NO, therefore NO increases.  
 The NO is also highly dependent on the presence of oxygen. Changing the carrier gas 
for the quantum yield experiments from helium to medical grade air, causes the production of 
NO to drop. At pH 4.5, the NO drops from 0.0052 to 0.0030 when oxygen is used to purge 
the reaction cell (λirr = 365 nm). The drop in NO release can be due to the production of a 
small amount of NOx species such as NO2 once oxygen is present,
14,15 since the NOA does 
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not identify NOx species, the production of these species cannot be included in the quantum 
yield. The oxygenated experiments however, still exhibit the same trend of an increased 
quantum yield with decreased pH resulting from the increased population of the ruthenium 
nitrosyl.  
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Chapter 4. Biological Studies of Ru(NO)(salen-CO2H)Cl 
4.1 Introduction 
 Compound 1 has potential pharmaceutical applications due to its ability to release NO 
within cells upon photoexcitation.  With valuable properties compatible with biological 
systems, such as high water solubility, photoactive release of NO, and pH dependent quantum 
yield, compound 1 will release NO only in cellular regions that have been irradiated with the 
necessary wavelength of light. The compound was therefore tested for toxicity in a murine 
melanoma cell line and for its ability to induce vasodilation in murine (rat) arteries. The 
majority of the work in this chapter was completed at the Univerdidade de São Palo, Ribeirão 
Preto in Brazil in the labs of Dr. Roberto Santana da Silva and Dr. Lusiane M. Bendhack. 
4.2 Cell Viability 
 Toxicity studies were completed using murine melanoma B16F10 cells. Melanoma 
B16F10 cell lines were grown to a concentration of 2 × 105 cells/ mL and 200 μL of such 
suspensions were aliquoted into each well of 96-well plates with RPMI growth media. The 
cells were incubated within the 96-well plate for 24 h, allowing the cells to affix to the surface 
of the 96-well plate.  
 Stock solutions of compound 1 in RBMI media were prepared at concentrations of 20 
mM, 10 mM, 2 mM, and 1 mM. Each well contained 200 L of media and a 2 L aliquot of 
the stock solutions with varying concentration was added to each well. The final concentration 
of 1 was 200 M, 100 M, 20 M, 10 M, and 0 M as a control. Cells were incubated in the 
dark for 4 h followed by exposure for 4 min to 470 nm light or shielded from light and then 
incubated traditionally, in the dark for an additional 24 or 48 h. Experiments that were exposed 
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to light were done so on a custom plate mount with individual 470 nm LEDs in each well of 
the 96-well plate and calibrated to a power of 13.69 mW. The reported values are an average 
of triplicate samples in three different experiments. 
 Cell viability was determined using the well-established MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-ditetrazolium bromide) assay to determine the population of living 
cells via NAD(P)-H enzymatic activity.1 For the MTT assay, after completion of incubation 
time the media is replaced with MTT solution (12 mM thiazolyl blue tetrazolium bromide in 
phosphate buffer was diluted in media to a final concentration of 1.2 mM). The MMT is 
absorbed through the plasma membrane of living cells and processed by the mitochondria to 
produce a formazan dye that absorbs strongly at 570 nm. The absorbance spectra is recorded 
and a higher absorbance in a sample indicates a higher concentration of living cells. Wells 
incubated without exposure to 1 were used as control.  
 After 24 h, cells incubated with a concentration of 10 μM of 1 showed no statistical 
difference from the control as determined by Tukey’s post-hoc test with cell viability at 94% 
and 97% for dark and light exposed samples. As the concentration of 1 was incrementally 
increased to 200 μM, cell survival decreased moderately to about 60% after 24 h. There was 
little statistical difference between the photolyzed (light exposed) and unphotolyzed (dark) 
cell samples until the concentration of 1 was increased to 200 μM. At this concentration, the 
cells exposed to light have statistically less cell death, with cell viabilities of 68% compared 
to 60% for cells not exposed to 470 nm light (P < 0.0001) (Figure 1).  However, this difference 
is quite modest. 
 With an increased incubation time of cells with 1 (to 48 h), there was a similar slight 
increase in viability for those solution that had 4 minutes exposure to light. At a concentration 
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of 100 μM 1, the photolyzed cells display a cell viability of 64%, while incubation in the dark 
without any light exposure results in 58% viability, while at 200 μM of 1 the difference is 
51% dark: 59% light. (P< 0.01 and P< 0.0001, respectfully, Figure 2). Thus, after 48 h 
incubation and at the maximum concentration of 200 M, cell survival remains above 50% 
for both irradiated and non-irradiated samples. Therefore 1 is only moderately toxic towards 
B16F10 cells up to 100 μM. NO is cytoprotective at low concentrations,2 therefore the 
increased cell viability in the photolyzed samples is possibly due to a small production of NO 
or that the photoproduct is less cytotoxic that 1. Statistical analyses were completed on the 
cell viability of the light and dark samples by student t- test and resulted in P < 0.05, 
confirming statistical significance. Due to solubility limitations at a maximum concentration 
of 200 μM, an LD50 could not be determined. 
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Figure 4.1. Cell viability plots with exposure to increasing concentrations and duration of 
compound 1. The plates under light were irradiated for 4 min at 470nm (4 J/cm2) while plates 
under dark were not exposed to light. Cell viability was assessed by the MTT assay and results 
expressed as a percentage relative to the control (absence of compound 1). The values are the 
mean ± SEM. * p < 0.05 in comparison to others treatments and the control obtained by 
ANOVA analyses using Tukey’s post-hoc test. 
 
 74 
 
Figure 4.2. Cell viability of cells incubated in the dark (black) or after irradiated at 470 nm 
for 4 min (white). Cells incubated with either 100 μM or 200 μM of 1 followed by an 
incubation of 24 or 48 h as listed. P < .01 (**), P < .001 (***). 
4.3 Myography Studies 
 As a signaling molecule, NO plays a large role in the dilation of veins and arteries to 
help control blood pressure.2 Myography or vasodilation can therefore be used to identify the 
production of NO in a biologically relevant environment. The present studies were completed 
using Krebs buffer solution with bubbling oxygen and carbon dioxide (with or without light 
as specified). Therefore the relaxation of the aortic rings in this study would show irradiation 
of the compound 1 can generate biologically relevant concentration of NO.   
4.3.1 Vascular reactivity 
 Myography studies were completed to test the release of NO from 1 inducing the 
relaxation of rat aortic rings. The experiment was performed in a pH 7.4 Krebs buffer solution 
(composition in mM: NaCl (130.0), KCl (4.7), KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (14.9), 
0
10
20
30
40
50
60
70
80
200 μM 100 μM 200 μM
C
el
l 
V
ia
il
it
y
 (
%
)
***
** ***
24h 48h 48h 
 75 
glucose (5.5) and CaCl2 (1.6), adjusted to pH 7.4) and the concentration of 1 was slowly 
increased by sequentially adding aliquots of a stock solution of 1 over time. At the initial 
concentration of 10-10 M, there was no obvious effect on the aortic relaxation (Figure 3) in the 
dark or under ambient light.  As the concentration of 1 was increased stepwise the effects 
shown in Figure 3 were evident. Under ambient light, a 10-6 M concentration of compound 1, 
was sufficient enough to induce vasodilation. Complete relaxation was established at 10-5 M.  
Alternatively, when the assay was performed in the dark with ambient light excluded, 
vasodilation was not observed even when the concentration of 1 was increased to 10-4 M.  
Upon the addition of 1 at a concentration of 10-5 M directly into the experimental setup 
containing a fully contracted aortic ring, relaxation was slow in ambient light and required 
approximately 50 min to attain full relaxation (Figure 4). The amount of vasodilation induced 
by 1 over the course of 60 minutes is plotted as the area under the curve (AUC) for the system 
exposed to ambient light and the system kept entirely in the dark. It is evident that 1 induced 
vasorelaxation in ambient light while having little relaxation in the dark (Figure 4, inset). No 
discernable difference in response was seen between aortic arteries with or without 
endothelium cells. These results confirm that NO was produced from 1 in combination with 
ambient light and not by residual NO within the experimental setup. 
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Figure 4.3. Vascular relaxation induced by Ru(NO)(salen-CO2H)Cl in denuded rat aortic 
rings in ambient light or dark. Data are mean ± SEM (n=6). 
 
Figure 4.4. Time-course for Ru(NO)(salen-CO2H)Cl -induced relaxation. Denuded thoracic 
aortic rings were pre-contracted with 0.1 μmol/L phenylephrine and 0.1 μmol/L 
Ru(NO)(salen-CO2H)Cl was added. Area under curve (AUC) was used to express to total 
relaxation induced by compound 1 in ambient light or dark over 60 min. Data are means ± 
SEM of n = 3-6 experiments performed on preparations obtained from different animals.  
4.4 Chemical and electrochemical release of Nitric Oxide 
 Nitric oxide has been shown to be released through several mechanisms, such as thermal, 
chemical, and photo activated release.3, 4 Although this work has focused on the release of 
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NO through photolysis, other methods to cleave the ruthenium nitrosyl bond were also 
explored. The two methods employed were electrochemical (through voltammetric studies) 
and chemical release through the use of ascorbic acid. The results of these two studies are 
discussed below.  
4.4.1 Voltammetric experiments 
 Differential pulse voltammograms of 1 were used to identify the reduction peak of {Ru-
NO}3+/2. Experimentally, a charging potential at -0.5 V was required to induce NO release 
electrochemically from compound 1. The charging potential was maintained for a specific 
duration ranging from 0 – 300 seconds (Figure 5a). The oxidation peak at -0.3 V vs Ag/AgCl 
is attributed to the {Ru-NO}3+/2+ reduction centering on the nitrosyl ligand, as seen in similar 
compounds.5 As the charging potential was maintained, the peak intensity at -0.3 V decreased 
corresponding to the loss or labilization of the nitrosyl ligand and formation of a solvent 
species (Scheme 1). Additionally, there is a peak growth at 0.1 V vs Ag/AgCl during the 
anodic run attributed to the formation of the solvent species {Ru-H2O}
2+/3+ after the reduction 
process, and this new peak is not observed during the cathodic run where the charging 
potential is set at +0.5 V (Figure 5b). The isosbestic point within the anodic run further 
confirms the release of NO and conversion from one species to the solvent species.  
 
Scheme 4.1. Photochemical release of nitric oxide and solvent coordination to ruthenium 
center. 
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Figure 4.5. Differential pulse voltammetric scans with carbon glass electrode with silver 
chloride reference electrode. Scans recorded after specified timed charging with conditioning 
potential of -0.5 V and run between (top) -0.5 – 0.5 V and (bottom) 0.3 – -0.5 V. 
4.4.2 Ascorbic Acid Studies 
Ascorbic acid was selected as an oxidant to examine chemical interaction of 1 with a 
representative redox capable molecule (especially one that is common in biological systems), 
due to the charge potential observed in the voltammetric experiments above. Literature values 
show that a 0.01 M ascorbic acid solution has a potential of 0.06 V at pH 7.4.6 The reduction 
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potential necessary for NO generation at 0.3 V can be achieved by the addition of 0.14 M 
ascorbic acid to induce NO release from a solution containing 28 μM of 1. The procedure was 
performed following a protocol described previously.7 The NO electrode and a 3.0 
mL solution of 1 were kept under argon atmosphere, magnetic stirring and protected from 
light. The release of NO was monitored by UV-visible spectral changes and the generation of 
NO by utilizing a NO specific electrode (inNO Nitric Oxide measuring system by Innovactive 
Instruments Inc.) in pH 7.4 phosphate buffer solution. After the baseline had been established, 
0.5 mL of 1 M ascorbic acid (final concentration 0.14 M) was injected by an airtight syringe 
at 100 seconds, resulting in generation of NO observed by an increase in the measured current 
(Figure 6). The release of NO resulted in a UV-visible spectral change indicating the chemical 
release of NO (Figure 7).  
 
 
Figure 4.6. Release of NO upon addition of ascorbic acid to a solution of 1. Current measured 
using an NO specific electrode. * indicates the addition of 0.14 M ascorbic acid solution to 
evaluate the NO release upon redox reaction. 
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Figure 4.7. UV-visible spectra of 1 before and after the addition of [0.14 M] ascorbic acid to 
a pH 7.4 phosphate buffered solution. The change in spectra is due to the loss of NO as shown 
in photochemical studies. Black: absorbance spectra prior to ascorbic acid addition. Red: 
absorbance spectra after ascorbic acid induced release of NO. The absorbance spectra after 
ascorbic acid addition has been corrected for the change in volume. 
4.5 Conclusion 
 Compound 1 possesses low cytotoxicity up to 100 μM and shows slight improvement 
of cell viability when irradiated with a low intensity 470 nm light source generating a small 
amount of NO. Experiments performed in aortic rings also confirm the ability of 1 to induce 
vasodilation at low concentrations (as low as 1 µM) with only ambient light illumination, 
whereas incubation in the dark does not result in any vasodilation even at a concentration of 
100 µM. The aortic relaxation in ambient light resulted in the slow production of NO and 
complete vasodilation required 50 minutes. The long time scale provides beneficial regulation 
as the slow relaxation reduced the risk of a dramatic drop in blood pressure after drug 
administration. The release of NO has also been observed in several alternative processes, 
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particularly through electrochemical incubation and chemical processes resulting from the 
addition of ascorbic acid monitored by spectral changes and a NO specific electrode.  
 As described in chapter 3, there is a strong pH dependence to the quantum yield of NO 
release. Previous research has identified that human tumors are highly hypoxic which results 
in a drop of pH to 5.7 – 7.88 while the lysosomes have a pH range of 4.5 – 5.0.9 Such low pH 
environments can result in higher quantum yields within hypoxic cells and the generation of 
more NO at lower wavelengths of light or shorter irradiation timescales. Therefore, the NO 
concentration and subsequent radical concentration would be higher in hypoxic cells where 
radiation therapy is least effective, possibly improving radiation treatment to localized 
regions. Future research should be performed in hypoxic tissue to study both the release of 
NO and any possible therapeutic applications, as the higher concentrations likely to result 
from reduced pH in hypoxic tissue may no longer be beneficial to cell growth but rather result 
in inhibition and, ideally, reduction in cell viability of cancerous tissue. 
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Chapter 5. Ru(NO)(Salophen)Cl and Encapsulation in Secondary 
Structures  
5.1 Introduction 
 Ru(NO)(salophen)Cl (2) was synthesized for two important reasons: its hydrophobic 
nature and red-shifted spectral properties. The hydrophobic character of 2 allows it to be 
incorporated into the lipophilic polymers PLGA (poly(lactic-co-glycolic acid)) and PDMS 
(Polydimethylsiloxane) and makes it less likely to leach into a surrounding aqueous 
environment, thus providing a valuable drug delivery option. The same polymer can also 
incorporate light harvesting antenna, such as nano particles, allowing for energy transfer 
processes to induce NO release upon long wavelength light excitation of the polymer-salophen 
complex.  
 The use of an antenna as a light harvesting technique for drug release has been studied 
extensively within the Ford group1 and others.2, 3 In previous studies, Cr(cyclam)(ONO)2
+ 
(Figure 5.1) was suspended in a solution with negatively charged quantum dot, CdSe/ZnS 
core/shell nanoparticles that would associate with the positively charged species via ion 
pairing.1 This nonspecific interaction of the added nanoparticles increased the release of NO 
tenfold versus simple photolysis the Cr(cyclam)(ONO)2
+ in solution without nanoparticles.1 
This work indicated that energy transfer from nanoparticles to a photoNORM could enhance 
Figure 5.1. PhotoNORMs Ru(NO)(salen-CO2H)Cl (compound 1) discussed in chapters 3 
and 4, Ru(NO)(salophen)Cl (compound 2) and Cr(cyclam)(ONO)2+. 
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NO release, even with only nonspecific ionic interaction. For biological applications, which 
possess many positively and negatively charged species, an approach with improved 
specificity is needed to release NO without concern of nonspecific ion pairing or diffusion 
limited processes for nanoparticle-photoNORM association. Encapsulating the light 
harvesting antenna and photoNORM into a biologically stable polymer could allow for the 
close association needed for energy transfer and release of NO while limiting concerns of 
background biological interactions. 
5.2 PhotoNORM Encapsulation 
 Two separate biocompatible polymers were used in testing the encapsulation of 
photoNORMs. Biocompatible silicone polymers are used as coatings in many medical 
implants and for a variety of surgical procedures such as coatings for pacemaker leads and 
breast implants4 while PLGA (Poly(lactic-co-glycolic acid)is a biodegradable polymer that 
can be synthesized to have time dependent degradation varying from hours to years according 
to the monomer ratios within the polymer.5 PLGA particles have been loaded with drugs and 
used in cancer treatments, vaccinations, and used in the treatment of inflammatory diseases.3 
The biological inertness of these polymers allows their use for a drug delivery scaffold, as 
concerns for background interactions are already minimized with FDA approval in a variety 
of applications. However, discovery of the optimal system for utilization of silicone polymers 
for drug discovery purposes is difficult, as controlled release of the drug molecule can be 
complicated.2, 3 Including a photoactive drug in the polymer would allow for a more controlled 
drug release and the ability to modulate drug release depending on the condition of the patient. 
Unfortunately, many photo active drugs absorb in the near UV, a wavelength region that has 
poor penetration through tissue.6 The efficient release of cargo from the photoactive drug by 
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using more penetrating longer wavelength near-infrared (NIR) light can be aided by the 
addition of a two-photon absorbing compound, which then releases a single photon of higher 
energy light. By closely associating a two-photon NIR absorbing molecule to a photoactive 
species with absorbance overlapping the two-photon emission, photo-uncaging can occur and 
the drug can be released.  
 This chapter focuses on the two-photon up-converting nanoparticle (UCNP) NaYF4: 
Yb30Gd20Tm0.2 @ NaYF4, which absorbs at 980 nm and emits at 365 nm, 450 nm, 475 nm, 
and 645 nm. The polymer PLGA was  selected due to its varied uses throughout the field3 
while PDMS (Polydimethylsiloxane) was selected due to its optical clarity, hydrophobicity, 
large pore size, insensitivity to NO, and ability to encapsulate UCNPs into the polymer 
structure and retain structural integrity.7 Both PLGA and PDMS has also been FDA approved 
for use in medical procedures including contacts, catheters, and implants.8 This chapter will 
include the preparation of the photoNORM and UCNP incorporated PLGA microparticles and 
into PDMS polymer, photolysis experiments, and NO release upon polymer excitation under 
a variety of conditions. The best performing NO releasing platform was studied further by 
irradiating through porcine tissue to determine the ability of the photoNORM/ UCNP system 
to produce NO with scattered and diffused light due to a tissue analog.  
5.3 Results and Discussion 
 The Ru-salophen photoNORM studied in this chapter was synthesized by procedures 
described in the Experimental (sec. 2.3.2). It product was purified by column chromatography 
and stored under vacuum at room temperature in the dark.  
 86 
5.3.1 UV-visible Spectral changes 
 The salophen ligand provided a considerable 125 nm red-shift in the absorbance 
spectra versus the ruthenium salen structure 1 [Ru(NO)(salen)Cl], shifting the MLCT band 
from 315 nm to 440 nm in acetonitrile (Figure 5.2). The second peak at 253 nm was also red-
shifted by 62 nm to 315 nm, a bathochromic shift directly related to the additional conjugated 
ring in the ligand. The Ru(NO)(salophen)Cl complex was observed to maintain thermal, 
oxygen, and water stability similar to the Ru(NO)(salen) compound with the advantage of 
photoactive NO release upon irradiation at lower energy light.  
 
Figure 5.2. Spectroscopic shift in absorbance from 1 (red dash) to 2 (solid blue) in acetonitrile 
at equal concentration. Absorbance peaks of 1 at 253 nm and 315 nm shift out to 315 nm and 
440 nm for compound 2. 
5.3.2 Quantum Yield studies 
 A stock solution of 60 μM concentration of 2 was created in isopropyl acetate and 
aliquot into 3 mL portions for each individual experiment. The sample was photolyzed in a 4-
sided, Y-shaped cuvette which allows the carrier gas (medical grade air, bubbled through 5 
mL isopropyl acetate prior to entering the photolysis cell) to flow through the cell and purge 
the experiment as NO is generated (Appendix ii). Photolysis timing was controlled with a 
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uniblitz optical shutter, ranging from 0.25 seconds up to 1 second in quarter second 
increments. After each photolysis, the Nitric Oxide Analyzer (NOA) was allowed to return to 
baseline for a minimum of 1 minute prior to the next irradiation time point. (A complete 
description of the Sievers 1080i NOA is described in Appendix i.) 
Isopropyl acetate was selected for quantum yield (QY) experiments due to functional 
group similarities to the PLGA polymer and because the high boiling point and vapor pressure 
of the solvent is required for NOA experiments to avoid evaporation into the instrument. These 
experiments were aimed at mimicking the dielectric properties of nitric oxide release within 
the polymer microparticles. The absorbance spectra (Figure 5.2) shows a max at 331nm, 451 
nm with molar absorptivities at 17,000 and 4,600 respectfully. The ruthenium salophen in 
isopropyl acetate with medical grade purging air gave a QYNO of 0.0312 or 3.12 % when 
irradiated with a 470 nm focused LED. 
 
Figure 5.3. QY calculations of 2 in isopropyl acetate when irradiated at 470 nm under 
oxygenated conditions.  
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5.3.3 Up-Converting Nanoparticles (UCNPs) 
 Up-conversion of light is a process in which multiple photons of light are absorbed 
simultaneously or successively to promote an electron into higher excited states.9 The 
emission of light is then of higher energy (lower wavelength) than either of the initially 
absorbed photons of light. In lanthanide doped UCNPs, the rare earth emitters have forbidden 
relaxation pathways, and this property leads to long lived excited states and can up-conversion 
due to sequential absorptions of photons.10 The thulium doped nanoparticles used in this study 
are NaYF4: Yb30Gd20Tm0.2 @ NaYF4. The yttrium 3
+ species absorbs 980 nm light to give the 
excited state 2F5/2, which can undergo inter-system crossing (ISC) to the thulium excited state 
3H5.
11 Sequential photons are then absorbed by the yttrium 2F5/2 excited state, transferring the 
excited photon to populate the 1D2, 
1G4, and 
3H4 excited states on Tm which can relax to either 
3H6 or 
3F4. These relaxations result in a spectra with 5 sharp emission lines at 365, 451, 481, 
646, and 800 nm corresponding to the relaxations 1D2→3H6, 1D2→3F4, 1G4→3H6, 1G4→3F4, 
and 3H4→3H6.12 
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Figure 5.4. Absorbance spectra of 2 (solid black line) overlaid with the emission of NaYF4: 
Yb30Gd20Tm0.2 @ NaYF4 when irradiated at 980 nm (dashed blue line). 
5.3.4 FRET 
 Förster resonance energy transfer (FRET) can be employed to convert the emission of 
the UCNP to the ruthenium nitrosyl in order to break the ruthenium-nitrosyl bond and release 
NO. FRET is an energy transfer mechanism that relies on the proximity of emitter to acceptor 
and the spectral overlap between two chromophores through dipole-dipole coupling. These 
two parameters are displayed in the FRET equation with the distance (r) inversely related to 
FRET efficiency and the spectral overlap of the two chromophores (J) is directly related to 
the efficiency of energy conversion. The mechanism also relies on the dipole-dipole 
orientation, k, which is assigned as 2/3 for two randomly oriented dipoles, the photo-
luminescent quantum yield PL, and the lifetime of the photoluminescence in the absence of 
an acceptor chromophore D(0). The UCNP and 2 were selected because of their strong overlap 
of emitter/ acceptor while the distance is controlled by encapsulating the two chromophores 
within the polymer disk.  
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𝑘𝐸𝑁 (𝑟) =  
𝐶Φ𝑃𝐿𝑘
2
𝜏𝐷(0)𝑟6𝑛4
𝐽(𝜆) 
5.4 PLGA micro particles 
5.4.1 Control 
A 32 nM solution of compound 2 in isopropyl acetate was purged by medical grade 
air for 5 minutes on the NOA. The sample was irradiated with 980 nm light for 4 minutes time 
with no change in the background noise on the NOA. As no particles are present that can 
absorb 980 nm light and transfer to higher energy, no release of NO was expected and none 
was observed. Therefore, the production of NO in all other experiments is due to the 
absorbance of light by the UCNPs and the subsequent emission and absorbance of the higher 
energy light to the photoNORM resulting in NO production. 
5.4.2 Preparation of PLGA nano particles containing UCNPs and 2  
 UCNPs and 2 were suspended in acetonitrile along with a dilute mixture of PLGA. 
The solution was added drop-wise through a 0.4 mm polypropylene tube into a beaker with 
1% aqueous polyvinyl alcohol solution into a beaker of water with a submersed sonicating 
wand, the addition speed was carefully controlled by a syringe pump at a rate of 10 mL/hour. 
As the acetonitrile evaporated, small micelles formed, encapsulating the hydrophobic PLGA 
with the hydrophobic UCNP and ruthenium species. The microparticles were collected by 
centrifugation and washed with water. This method resulted in spherical particles with a 
diameter of approximately 100 nm ± 50 nm.  
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5.4.3 QY measurements 
 A 3 mL solution of 100 nm PLGA nanoparticles loaded with UCNPs and compound 
2 was purged with medical grade air for 5 minutes prior to NOA experimentation. A 980 nm 
laser was used to excite the agitated solution with increasing exposure time and laser power 
to induce photolysis of the Ru-NO bond. Additionally, QY measurements were completed at 
470 nm irradiation to compare the QY of NO release to verify the photoactivity of 2 within 
the PLGA particles.  
5.4.4 QY Discussion 
 Experiments of PLGA nano particles loaded with UCNPs and the photoNORM, 
compound 2 gave very little NO release upon excitation at 980 nm in water (this wavelength 
that does not cause NO release from the ruthenium compound alone and requires up-
conversion from the UCNPs). In order to test the efficient release of NO through the PLGA 
matrix, the loaded PLGA micro particles were additionally photolyzed at 470 nm and 
suspended in water. 
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Figure 5.5. PLGA nanoparticles loaded with UCNP and 2 suspended in water. Absorbance 
was adjusted to the baseline at 700 nm for QY measurements (horizontal dashed black line). 
The absorbance was corrected at the wavelength of irradiation, 470 nm (vertical dashed yellow 
line). 
 
 
Figure 5.6. Cumulative QY of NO release from PLGA micro particles loaded with UCNPs 
and 2, suspended in water. QY is equal to the slope of the line, 0.0036 when irradiated at 470 
nm.  
Quantum yields of NO release in the PLGA matrix were adjusted for absorbance due 
to the large amount of scatter the PLGA particles caused in solution. Absorbed light for QY 
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calculations were based on the absorbance at 470 nm minus the average absorbance between 
700nm and 800nm, where the ruthenium compound has no absorbance. This is depicted 
visually in Figure 5.5 where the black line shows the adjusted baseline due to scattering and 
the dashed yellow line identifies the irradiation wavelength. 
Experimental calculations show the QYNO drops from an average of ΦNO = 0.0312 
when in solution of isopropyl acetate to ΦNO = 0.0036 when photolyzed with the UCNPs in 
the PLGA particle with 470 nm light (Figure 5.6). This drop can be associated with further 
light scattering within the particle that was unaccounted for. There may also be a process 
where the nitrosyl is stabilized on the ruthenium, effectively lowering the QY of NO release. 
NO may even react with the PLGA polymer before the NO is purged by the carrier gas, 
therefore only large quantities of NO will show any response on the NOA. Due to the low 
yield release of NO through microparticle photolysis with PLGA particles, other polymer 
manifolds were tested for their ability to release NO. 
5.5 PDMS Polymer Disk Experimental  
PDMS Polymer disks (PDs) were prepared by mixing the PDMS and curing agent in 
a 10 to 1 ratio by weight and vigorously stirred for 5 minutes (according to the manufacturer 
procedure, Sylgard® 184 elastomer kit Dow Corning). Air introduced by mixing of the two 
prepolymer solutions was removed by placing the liquid polymer under vacuum for 30 
minutes. UCNPs were added to the liquid polymer after it had partially set (approximately 1 
hour). The PDMS disks containing UCNPs were loaded with 2, 5, or 8 mg of NaYF4: 
Yb30Gd20Tm0.2 @ NaYF4 UCNPs. They were then annealed at room temperature for 48 hours 
in a Teflon mold to prepare 5 mm sized polymer disks. PDs with and without UCNPs were 
stored at room temperature on the bench top until use.  
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5.5.1 Incorporation of ruthenium salophen nitrosyl into the PD 
Polymer disks (PD) were impregnated with the hydrophobic ruthenium nitrosyl 
salophen complex, 2, by submerging the PD in a concentrated THF solution of the ruthenium 
compound in the dark. The PD was left in the concentrated solution for 10 minutes followed 
by the slow evaporation of the THF under vacuum. This process was repeated three times to 
ensure a high loading of 2 into the PD. To eliminate variability, the PD was allowed to fully 
dry between cycles.  
To remove excess 2 from the exterior surface of the loaded PDs, the disks were washed 
with a small volume of THF and placed under vacuum until fully dry. The excess ruthenium 
was then removed by several washing steps with nanopure water until the UV-Vis spectra of 
the water solution contained no evidence of ruthenium salophen absorbance after 1 hour. The 
final PDs were stored under vacuum to prevent water from settling on the surface which 
proved to be detrimental in previous studies.7  
5.5.2 Oscillating 980 nm laser 
 The size disparity between the pin laser width (0.7 mm) and the PD diameter (5 mm) 
forces the results to depend on the loading of a small fraction of the PD. Therefore to ensure 
consistency of NIR excitation across the entire surface of the PD, an oscillating 980 nm laser 
was used for photolysis experiments. The oscillating system allowed the 980 nm laser beam 
to scan across a broader portion of the PDs during a single run. This was achieved by mounting 
the angling mirrors to a vibrating mount controlled by a frequency generator. A Techtonic 
AFG320 digital generator was used to maintain a constant vibrational frequency for the 
mounted mirrors, ensuring a consistent photolysis path between samples. By adjusting the 
frequency of each mirror, the size of the scanned area was defined with each mirror controlling 
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the scanning width in one direction (horizontal or vertical control). The experiments were run 
with frequencies for the two mirrors at 78.93 Hz and 48.93 Hz respectfully, to give a vibrating 
mirror system which scanned the majority of the 5 mm PD.  
5.5.3 Loading the sample 
The PD was suspended in the specially designed NOA photolysis chamber on a glass 
coverslip and attached with a double-sided adhesive strip. The glass coverslip was inserted 
into a Teflon mount that fit into the base of the photolysis chamber. The crew cap lid was 
equipped with glass mounts that could suspend fat and tissue samples in front of the PD for 
photolysis studies through tissue, providing experimental insight into photo initiated NO 
release through real biological barriers. The vibrating laser was aligned to the mounted PD at 
low power to ensure accuracy of the moving laser before each experiment. Swagelock to glass 
attachments were used to connect the purge gas from the tank, through the reaction chamber 
and into the NOA for continuous NO monitoring. 
5.5.4 Control of Quantum Yield of Ru(NO)(salophen)Cl loaded PD at 980 nm 
 PDs loaded with 2 only were loaded into the photolysis chamber and allowed to purge 
with medical grade air for 5 minutes with continuous analysis by the NOA. After the baseline 
was established, the PD with compound 2 was exposed to the 980 nm oscillating laser with 
variable power and duration of exposure. No release of NO was observed even when these 
disks were exposed to 4 W of power for 60 seconds, which is twice the power and duration of 
any other NO releasing experiments completed in this study. 
Compound 2 has no absorbance at 980 nm, is thermally stable, and does not 
decompose in oxygen. Therefore, no release of NO was expected upon exposure to 980 nm 
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light. Additionally, 2 is stable in the PDMS polymer under the applied experimental 
conditions (save for obvious photolysis). This experiment proves that any further study where 
NO is seen to be produced upon photolysis is not caused by the direct absorbance of 980 nm 
light to the PhotoNORM 2, even at high laser power where heating of the polymer may occur.7  
5.5.5 Control of Quantum Yield of Ru(NO)(salophen)Cl loaded PD at 470 nm 
 Quantum yield measurements for loaded Ru(NO)(salophen)Cl in a PDMS PD were 
completed at λ = 470 nm (control experiment in isopropyl acetate is described in 5.3.2). The 
sample was loaded in the NOA photolysis chamber and the chamber was purged with medical 
grade are carrier gas. The LED beam was focused to the full diameter of the PD (therefore, 
the oscillating system was not used). The exposure time was controlled by a uniblitz shutter 
and the release of NO was monitored on the NOA.  
 The average of the triplicate samples are plotted with moles of NO versus the photons 
of light absorbed (Figure 5.7). Therefore, at 470 nm irradiation in a PD in solid state, ΦNO = 
0.00329. The decrease in Φ in the solid state versus in solution has been seen in several other 
processes due to scatter and rotational restriction in solid state. DFT calculations on similar 
ruthenium nitrosyls show that upon excitation into the metal to ligand charge transfer band 
(MLCT) the Ru-NO bond angle bends and the bond length changes as the compound relaxes 
back to ground state.13 The decrease in Φ can be associated with the loss of vibrational and 
rotational modes and the absence of a solvent to stabilize the photo product.  
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Figure 5.7. Quantum Yield of Ru(NO)(salophen)Cl at λ = 470 nm while suspended in a 
PDMS polymer disk with medical grade air carrier gas. Φ = 0.00329. 
5.5.6 Running samples 
Three sets of UCNP samples loaded with 2 were irradiated with the 980 nm oscillating 
laser system and data collected in real time for NO release on the NOA. Power settings began 
at 0.5 W and were increased in 0.5 W increments to 2 watts or until consistent signal was 
observed. The exposure time ranged from 2 to 30 seconds. Higher power and longer exposure 
times introduced the risk of burning the PD due to UCNP heating of the polymer, although 
this was not seen at the lower power and time regimes used, but had been observed in previous 
studies.7 
5.5.7 Results 
  Each PDs contained a defined mass of UCNPs within the polymer prior to the infusion 
of 2. PDs were either synthesized with 2 mg, 5 mg, or 8 mg of NaYF4: Yb30Gd20Tm0.2 @ 
NaYF4 UCNPs. The NO release was monitored using a Sieverson 1080i Nitric Oxide 
Analyzer (NOA). Individual data is described for each experimental parameter.  
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5.5.8 PDs with UCNP loading 
 PDs loaded with 2 mg, 5 mg, or 8 mg of NaYF4: Yb30Gd20Tm0.2 @ NaYF4 UCNPs 
were infused with 2 and fully dried as described in the experimental section. While working 
with multiphoton UCNPs, power and scan rate of the laser have a large effect on the generation 
of excited states.7 The scan rate is defined as the speed in which it takes the laser to cross the 
sample while power is measured in watts allowing more excited states to be generated on a 
UCNP. To test the relationship of power and time within these experiments, scan rate was 
held constant. Upon irradiation, NO was generated by the absorbance of 980 nm light by the 
UCNP followed by emission and subsequent absorbance by 2 resulting in NO production 
(Figure 5.4). The moles of NO generated were divided by the Einsteins of light (Io = Einsteins 
per second) from the 980 nm laser and plotted against time in Figures 5.7 – 5.9. The plotted 
data will be referred to as the efficiency of NO release instead of QY ( 
𝑚𝑜𝑙𝑒𝑠 𝑁𝑂
𝑝ℎ𝑜𝑡𝑜𝑛𝑠 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑
 ) 
because of the two step process of absorbance by the UCNP, emission, and subsequent 
absorbance by 2 to induce NO production. Since the efficiency term incorporates the photons 
of light, the change in power on the plots show a corrected value of NO production and show 
a definite increase in NO production dependent on the power of the light source and time.  
 Figure 5.7 – 5.9 shows the moles of NO/ Ia plotted against time of irradiation with the 
amount of NO being produced relative to the laser power clearly being a non-linear function. 
Lower production of NO at reduced power is consistent with previously reported studies 
showing that the multi- photon absorbers have a non-linear response for emission when 
irradiated by higher power light due to a charging effect on the UCNPs.7  
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Figure 5.8. Efficiency of NO release loaded with 2 mg UCNP. Moles of NO produced per 
photon plotted against irradiation time. The separate lines indicating the power of the 
irradiation source. The curves show are based on the assumption of an exponential function.  
 
 
Figure 5.9. Efficiency of NO release loaded with 5 mg UCNP. Moles of NO produced per 
irradiation time. The separate lines indicating the power of the irradiation source. 
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Figure 5.10. Efficiency of NO release loaded with 8 mg UCNP. Moles of NO produced per 
irradiation time. The separate lines indicating the power of the irradiation source with a non-
linear response. 
2 mg 1W 1.5W 2W 
5s  -- 8.3E-7  ± 9E-8 5.1E-7 ± 8E-8 
10s 3.6E-7 ± 2E-57 2.5E-6 ± 7E-7 1.1E-5 ± 6E-7 
15s  9.7E-7 ± 1E-7 8.6E-6 ± 1E-6 4.8E-5 ± 7 E-6 
20s 1.6E-6 ± 8E-7 1.7E-5 ± 2E-6 1.2E-4 ± 3E-6 
30s 3.8E-6 ± 6E-7 5.8E-5 ± 6E-6 -- 
Table 5.1. QY of PD loaded with 2mg UCNP and 2. QYs vary dependent on time and power. 
5 mg 0.5W 1W 1.5W 2W 
2s -- -- -- 2.4E-7 ± 9E-9 
5s -- -- -- 2.8E-6 ± 9E-7 
10s -- 1.8E-6 ± 6E-7 3.1E-6 ± 4E-7 3.9E-5 ± 1E-6 
15s  -- 3.1E-6 ± 3E-7 1.4E-5 ± 2E-6 -- 
20s -- 4.3E-6 ± 6E-7 7.3E-5 ± 2E-5 -- 
30s 4.1E-6 ± 1E-6 1.2E-5 ± 2E-6 -- -- 
Table 5.2. QY of PD loaded with 5mg UCNP and 2. QYs vary dependent on time and power. 
8 mg 0.5W 1W 1.5W 2W 
2s -- -- -- 7.1E-7 ± 4E-7 
3.5s -- -- -- 6.9E-6 ± 3E-7 
5s -- 4.5E-7 ± 2E-7 2.1E-6 ± 4E-7 4.9E-5 ± 7E-6 
10s 2.5E-6 ± 8E-7 5.8E-6 ± 2E-6 1.0E-4 ± 3E-5 -- 
15s  2.1E-6 ± 8E-7 2.1E-5 ± 3E-6 -- -- 
20s 5.8E-6 ± 2E-6 4.9E-5 ± 7E-6 -- -- 
30s 7.7E-6 ± 9E-7 1.4E-4 ± 2E-5 -- -- 
Table 5.3. QY of PD loaded with 8mg UCNP and 2. QYs vary dependent on time and power. 
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5.5.9 Time comparison of UCNP loading 
 The loading of UCNPs also has a large impact in the efficiency of NO released. At 
low laser power (0.5 W) NO release was only observed in PDs with higher UCNP loading 
therefore and higher power photolysis was required to generate repeatable NO release 
throughout all UCNP loadings. The same non-linear trend is observed within the same 
irradiation time as power is increased from 1 W to 2 W. Figure 5.10 shows the increase of NO 
production after continuous laser excitation for 10 seconds with increasing laser power and 
increasing concentration of UCNPs (2 mg to 8 mg). The data in Figure 5.10 shows the moles 
of NO divided by the photons of light absorbed which is directly related to power. Therefore, 
more NO is produced at higher power independent of the number of photons absorbed. The 
exponential relationship to power is exaggerated when time remains constant, showing proof 
of a charging effect on the UCNPs that results in greater production of NO (consistent with 
Burks et. al.7). The highest loading of UCNPs also shows a strong influence on the production 
of NO and was selected for further experiments with tissue. 
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Figure 5.11. Efficiency of NO release when photolyzed for 10 s. Variable changes relating to 
the increased number of photons produced are adjusted for on the x-axis. The change of 
loading of UCNPs are plotted separately and indicated by the 8 mg (red), 5 mg (green), and 
2mg (purple) designation.  
5.5.10 Tissue samples 
 The PD with the highest efficiency of NO release with 8 mg UCNP loading was 
selected for studies using porcine muscular tissue at 2.5 mm thickness as filters. The tissue 
was suspended in front of the PD in the path of the 980 nm laser. The carrier gas of medical 
grade air was bubbled through nanopure water prior to entering the photolysis chamber, so 
that the flowing air did not dry the tissue sample throughout the experiment. The PD was 
irradiated for varying amounts of time (from 10 s to 40 s) through the tissue at 2 W, resulting 
in the non-linear production of NO in respect to increased time (Figure 5.11, blue circles). 
Furthermore, the PD can be re-used as shown in Figure 5.11 (orange triangles) to have 
equivalent NO production at 20 and 30 seconds. The PD is therefore not exhausted of NO 
releasing capabilities after 5 minutes of photolysis at 2 Watts. Additionally, there was no 
change in the appearance or thickness of the tissue at this power and time scale.    
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Figure 5.12. Release of NO after the light is passed through 2.5 mm of porcine tissue and hits 
the 8mg UCNP and 2 loaded PD. The moles of NO generated were measured against time 
(blue circles) and show an exponential response versus time. After efficiency measurements, 
the same sample was photolyzed at 20s and 30s to show repeatability between experimental 
runs with the same PD (orange triangles). 
 To account for the photons of light transmitted to the system, the moles of NO were 
divided by the photons of light produced by the 2 W 980 nm laser. This amounts to an Io of 
1.51E-5 Einstein’s/ second. The efficiency of NO release is plotted in Figure 5.12 with respect 
to time as seen in the experiments without tissue. Without tissue present, an 8 mg UCNP 
loaded PD when irradiated at 2 W will have a QY of NO release 4.9E-5 ± 7E-6 at 5 second 
irradiation (Table 5.3). While tissue is present the efficiency decreases as light is absorbed 
and scattered by the tissue resulting in a lower QY of 7.2E-7 ± 2E-7 at twice the time, 10 
second irradiation (Table 5.4). Despite the dramatic drop in the rate of NO production when 
tissue is filtering laser excitation, the QY of the individual PD is still sufficiently high to 
withstand moderate scatter and does not require a high power laser to induce photoactived 
release.  
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Figure 5.13. Efficiency of NO release from an 8 mg loaded UCNP after the light has passed 
through 2.5 mm of porcine tissue. Moles of NO produced per irradiation time while power 
remains constant at 2 W. 
Irradiation Time Quantum Yield  
2W (no tissue) 
2s 7.1E-7 ± 4E-7 
3.5s 6.9E-6 ± 3E-7 
5s 4.9E-5 ± 7E-6 
  
Table 5.4. QY of NO release of PD loaded with 8mg UCNP and 2 irradiated at 980 nm with 
no tissue (left) or after irradiation through 2.5 mm porcine tissue (right). QYs vary dependent 
on time and power. 
5.6 Conclusion  
 Biologically compatible microcarriers and implants are of great interest in the 
biomedical field as a method to deliver a drug to site specific locations. This chapter has 
focused on the release of NO using PLGA microparticles or PDMS polymer disks. The PLGA 
proved problematic in the generation of NO and reduced the efficiency of NO release, possibly 
stabilizing the bound ruthenium nitrosyl bond or reacting with free NO. However, the PDMS 
polymer disks loaded with UCNPs showed strong release of NO when irradiated at 980 nm 
light, even through tissue.  
Irradiation Time Quantum Yield  
2W with Tissue 
10s 7.2E-7 ± 2E-7 
20s 2.3E-6 ± 4E-7 
30s 6.9E-6 ± 6E-7 
40s 2.4E-5 ± 2E-7 
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The loaded PD with 8 mg UCNP and 2 provided the highest production of NO through 
excitation at 980 nm. The generation of NO is dependent on both the intensity of incident light 
and the duration of excitation on the PD. However, the light used can transmit through tissue 
and cause NO production through the excitation of the thulium doped UCNP, emission and 
subsequent absorbance by 2. This system could be used for coatings in surgical implants where 
the generation of a site specific drug would be beneficial to the healing process or reduce the 
risk of implant rejection. Use of small fiber optic LEDs could then be used to maneuver 
through a patient rather than using a high powered lasers to allow for deeper penetration and 
better control over site specific drug release.  
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Appendix i. Sievers NOA 1080i 
Ai.1 Example Calibration Curve 
(Range 5 pmol – 500 pmol) 
 
*Note, Sodium Nitrite (NaNO2) is hydroscopic.  Completely dry the crystals under vacuum 
before making standards to ensure accuracy.  
Stock Solution 1.00 mM NaNO2 solution: 
MW = 68.9953 g/mol.   Weigh out 69 mg NaNO2 and bring the total volume up to 1 L in a 
volumetric flask with nanopure water.   
Dilution factors:  
Samples were prepared with serial dilution 
Sample Conc. [NO] Vol. H2O 
Vol. [NO2
-] 
added 
Moles injected 
in 5 L injection 
1 100 M 900 L 
100 L of stock 
solution 
500 pmol 
2 50 M 200 L 
200 L of 
solution 1 
250 pmol 
3 10 M 900 L 
100 L of 
solution 1 
50 pmol 
4 5 M 200 L 
100 L of 
solution 3 
25 pmol 
5 1 M 900 L 
200 L of 
solution 3 
5 pmol 
 
Example:  
For sample 1. In a clean test tube or vial, add 100 L of the stock solution (1.00 mM) 
and dilute it with 900 L of nanopure water to bring the total volume to 1,000 L with a 
concentration of 100 M. Mix well. 
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For sample 2: In a clean test tube or vial, add 200 L of the solution prepared in sample 
1 (100 M) and dilute it with 200 L of nanopure water to bring the total volume to 400 L 
with a concentration of 50 M. Mix well.  
For sample 3: In a clean test tube or vial, add 100 L of the solution prepared in sample 
1 (100 M) and dilute it with 900 L of nanopure water to bring the total volume to 1,000 L 
with a concentration of 10 M. Mix well.  
Preparing the NOA:  
Turn on NOA as described in the SOP “Start up”. Prepare potassium iodine/ glacial 
acetic acid solution for the injection into the purge vessel and allow the vessel to purge for 10-
15 minutes.  
Injections: 
 Begin experiment on the NOA. Note the cell pressure in your lab notebook. Different 
cell pressures with require different calibration curves. Ideal cell pressure is 6.2 torr, however 
experiments can be completed with cell pressures as low at 4.2 torr. Changing the cell pressure 
for experiments will require a calibration curve at the new cell pressure within 0.1 torr.  
Allow the background to collect for 5 minutes to ensure the NOA has a stable baseline 
before you begin. Using a 10 L airtight syringe, inject 5 L of your prepared sample (starting 
with the most dilute) into the purge vessel and inject in a single smooth motion. Once baseline 
is returned, wait 1 minute and repeat injection. The syringe should be washed a minimum of 
3 times between injections with nanopure water and twice with the solution you will inject, 
discarding the solution as waste after each wash.  Each concentration should be injected a 
minimum of 3 times.    
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Click “Mark Injection” to give a name to each peak. “Mark Injection” can be selected 
before or after an injection and the cursor moved. Name each injection with the concentration 
injected. E.g. 5 M  
The location of the cursor will not influence where the start or stop point for integration 
occurs.  
Integrating Peaks:  
 Once the run is completed select “STOP” at the top center of your screen. (You will 
DELETE your entire run if you select “ABORT”.)  
 Adjust your threshold to be equal with the center of the baseline- such that the average 
of the noise would give you zero. Adjust the peak width to only include the injections you 
have made.  
If your peaks are not identifiable, select “Integrate Manually”, set cursor at the 
beginning of your first peak and select “Start”. A new cursor will appear, move this to where 
the peak has returned to baseline, select “Stop”. The start cursor will turn green, the sop cursor 
will turn red – you can move these after the fact. Continue this until you have identified all 
peaks.  
 Identify each peak with the peak name. Select “Next” or add a peak names at this 
point.  On the right of the plot, un-select the “use intercept” and select “Create Calibration”. 
Save the calibration curve.  
Calculating Calibration:  
 The calibration curve must be completed in a separate program. The NOA will give 
calibration curves in units of concentration not moles.  Input data of Area and Moles of NO 
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injected into Excel and plot. Plot the moles of NO versus the Area and add a linear trend line. 
Use the slope and intercept for measurement calculations.  
Example Calibration Curve: 
 
Injected concentration Moles injected Area 
1 M 5E-12 62.8 
1 M 5E-12 74.6 
1 M 5E-12 60.8 
5 M 2.5E-11 207.1 
5 M 2.5E-11 192.7 
5 M 2.5E-11 171.2 
10 M 5E-11 316.4 
10 M 5E-11 341.1 
10 M 5E-11 339.5 
50 M 2.5E-10 1589.4 
50 M 2.5E-10 1629.7 
50 M 2.5E-10 1592.2 
100 M 5E-10 3200.5 
100 M 5E-10 3242.3 
100 M 5E-10 3283.3 
 
 
Figure 1. Example plotted calibration curve on the NOA. Data compiled and plotted in Excel.  
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Ai.2 Solution phase NOA experiments 
 Solution phase NOA experiments are conducted in the same manner. To maintain the 
solvent level in the cuvette, the carrier gas is initially bubbled through the NOA purge vessel 
prior to flowing into the cuvette. A 3 mL sample is photolyzed in a custom 4-sided, Y-shaped 
quartz cuvette which allows the carrier gas to flow through the cell and purge the experiment 
as NO is generated.  
Photolysis timing is controlled with a uniblitz optical shutter, LED or laser is focused 
on the sample through manipulation of optical lenses. Following each photolysis, the Nitric 
Oxide Analyzer (NOA) must return to baseline prior to the next irradiation time point. 
 
Figure i.1. Visual depiction of the solution phase NOA quantum yield system.  
Ai.3 Solid phase NOA experiments 
 The solid phase NOA chamber is depicted in Figure i.2. The custom glass chamber is 
comprised of swage lock attachments to the carrier gas line and the NOA, a removable Teflon 
mount that holds a glass slide with the polymer disk sample (adhered with double sided tape). 
The cap of the solid state NOA cell has a glass fixture that can suspend tissue samples. When 
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tissue or skin is used in the NO release experiments, it is customary to attach the NOA purge 
vessel (Figure i.1) and bubble the carrier gas through water prior to entering the solid state 
chamber to avoid drying of the tissue over the course of the experiment.  
 
Figure i.2. Cartoon depiction of the solid state NOA chamber.
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Appendix ii. Additional Ruthenium Nitrosyls 
Aii. Introduction 
Several additional compounds have been synthesized and characterized for their ability to 
release NO upon photo excitation. These compounds were not used due to poor water 
solubility or discarded as the project shifted focus. However, these compounds are of interest 
due to their organic solubility and salen and salophen modifications. The phenol or methyl 
ester modifications could therefore be used in other projects where the functionalized groups 
can be used to integrate into polymers or chemically linked to a secondary structure. This 
chapter will encompass the synthesis and NO releasing abilities of phenol and methyl ester 
modified salens and the synthesis and characterization of the methyl ester salophen ligand 
along with the synthesis of common ruthenium precursor Ru(PPh3)2. 
Aii.2 Synthesis of Additional Ligands 
Aii.2.4 Salen-CO2CH3 
The synthesis of Salen-CO2CH3 [methyl dimethyl 3,3'-((1E,1'E)-(ethane-1,2-
diylbis(azanylylidene))bis(methanylylidene))bis(4-hydroxybenzoate)] was completed by a 
Shiff base reaction of methyl 3-formyl-4-hydroxybenzoate and ethylenediamine.  
 Methyl 3-formyl-4-hydroxybenzoate was purchased from Sigma Aldrich and was used 
without further purification. Methyl 3-formyl-4-hydroxybenzoate (0.5013g, 2.7 mmol) was 
dissolved in approximately 30 mL of ethanol and heated slightly to aid in dissolving the 
benzaldehyde completely. Ethelenediamine (0.0909g, 1.5 mmol) was dissolved into 5 mL of 
ethanol and added drop wise to the warm benzaldehyde solution.  The solution was heated 
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slightly with stirring for 30 minutes until the flask had completely turned opaque yellow from 
the initially clear solution.  
 The solution was allowed to cool to room temperature and the precipitate was filtered 
and washed with ethanol to product 0.5090g Salen-CO2CH3. To extract additional product, 
supernatant was concentrated to 5 mL via rotary evaporation and the salen was allowed to 
settle out of the ethanol solution producing an additional 0.0048g.  
 Total mass produced of 0.5138 g (1.34 mmol) Salen-MeEs at a 96% yield. Reaction 
shown is Scheme ii.1. 1H NMR taken on a Varian 400 MHz NMR in deuterated DCM. = 
8.435 ethylene (s, 2 H), aromatics = 6.947 (d, 2H), = 7.941 (d, 2H), = 7.991 (d, 2H), ethane 
bridge = 3.971 (s, 4H), methyl ester = 3.846 (s, 6H). (Figure ii.1) Peaks at = 3.406 and = 
1.586 are attributed to ethanol and water contamination from the reaction.1 Elemental Analysis 
C 62.50%, H 5.00%, N 7.20%. Theoretical C 62.49%, H 5.24%, N 7.29%. 
 
Scheme ii.1. Synthesis of Salen-CO2CH3  
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Figure ii.1. 1H NMR of Salen-CO2CH3 taken on a Varian 400 MHz NMR in deuterated DCM 
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Aii.2.5 Salen-OH 
Synthesis of salen-OH [N,N’-bis(salicylidene)ethylenediamine-4-hydroxide] was 
completed by a Shiff base reaction of ethylenediamine and 2,4-dihydroxybenzaldehyde. 
 The benzaldehyde, 2,4-dihydroxybenzaldehyde (1.0002 g, 7.24 mmoles) was 
dissolved in approximately 100 mL of ethanol and heated slightly until the 2,4-
dihydroxybenzaldehyde fully dissolved. Ethylenediamine (0.2008 g, 3.34 mmoles) was added 
to the warm solution and the solution was brought up to refluxed and stirred for one hour.  The 
solution was allowed to cool to room temperature before the precipitate was filtered and 
collected.  This produced 0.6286 g of the salen-OH product (Scheme ii.2).  
 1H-NMR in d6 DMSO,  methane proton, s (8.36p), aromatic protons, d (7.17, 7.15), d 
(6.26, 6.24), s (6.14), amine bridge, d (3.77, 3.33) (Figure ii.2). Elemental Analysis; C 63.72%, 
H 5.38%, N 9.71%. Theoretical; C 63.99%, H 5.37%, N 9.33%. 
 
Scheme ii.2. Synthesis of Salen-OH  
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Figure ii.2. 1H NMR of Salen-COH taken on a Varian 400 MHz NMR in (CD3)2SO. 
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Aii.2.6 Salophen-MeEs 
The synthesis of Salophen-CO2CH3 [dimethyl 3,3'-((1E,1'E)-(1,2-
phenylenebis(azanylylidene))bis(methanylylidene))bis(4-hydroxybenzoate)] was completed 
by a Shiff base reaction of o-phenylenediamine and methyl 3-formyl-4-hydroxybenzoate. 
The benzaldehyde, methyl 3-formyl-4-hydroxybenzoate (0.3409 g) was dissolved in 
approximately 25 mL of ethanol with stirring and mild heating. In a separate flask, 0.1025  g 
o-phenylenediamine was dissolved in 10 mL of ethanol and added drop wise into the 
benzaldehyde solution. The mixture was heated to reflux and stirred for 45 minutes. The 
solution was allowed to cool to room temperature and solid precipitate was collected and 
washed with cold ethanol. Solid product was left under vacuum for 2 hours to remove excess 
ethanol. 1H NMR in d2-methylenechloride on a 500 mHz Varian NMR showed the filtered 
product was pure. Solid was used without further purification (Scheme ii.3). 1H NMR 500 
mHz Varian (CD2Cl2) 8.73 (s, 2H), 8.18 (d, 2H), 8.04 (dd, 2H), 7.42 (ddd, 2H), 7.30 (ddd, 
2H), 7.05 (d, 2H), 3.88 (s, 6H), and phenol group at 13.67 (s, 2H) (Figure ii.3). Elemental 
Analysis C 60.50%, H 3.60%, N 7.40%. Theoretical C 66.66%, H 4.663%, N 6.48%. 
Scheme ii.3. Synthesis of Salophen-CO2CH3  
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Figure ii.3. 1H NMR of Salophen-CO2CH3 in d
2-methylenechloride on a 500 mHz Varian 
NMR. 
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Aii.3 Synthesis of Ruthenium Nitrosyls 
Aii.3.3 Ru(NO)(Salen-CO2CH3)Cl 
Salen-CO3CH3 (0.0201g, 0.052 mmol, 1 eq.) and NaH (0.0082g, 0.14 mmol, 2.7 eq.) 
in 57% oil dispersion were degassed and put under argon.  Approximately 30 mL of degassed 
ethanol was cannula transferred into the round bottomed flask and the solution was refluxed 
and stirred under argon for 1 hour.  
 In the dark, 0.0135g RuCl3(NO)∙H2O (0.053 mmol, 1 eq.) was dissolved in 
approximately 10 mL of degassed THF and cannula transferred into the hot salen solution in 
the dark. Ruthenium nitrosyl insertion required refluxing under argon in the dark for 3 hours 
(Scheme ii.4). The reaction mixture was allowed to cool to room temperature and the solution 
was cannula filtered off, precipitate collected.  
If the precipitate is impure, crude product was purified by silica column 
chromatography run in the dark 60:40 toluene: acetonitrile. Brown fractions removed slightly 
after the solvent line were shown to be the product by TLC and later by 1H NMR in deuterated 
acetonitrile. 1H NMR taken on a Varian 500 MHz NMR in deuterated acetonitrile. = 8.435 
ethylene (s, 2 H), aromatics = 7.065 (d, 2H), = 8.169 (d, 2H), = 8.376 (d, 2H), ethane 
bridge = 3.817, 4.335 (q, qq, 4H), methyl ester = 3.860 (s, 6H). Ethane bridge and methyl 
ester peaks seem to overlap due to the shouldering on the singlet of the methyl ester peak. 
This can account for slightly skewed integration of the peaks. (Figure ii.4). 
Peaks at = 2.131 and = 1.361 are attributed to water and ethanol contamination from 
the reaction. Additional peak after silica gel column at = 11.305 (s) is indicative of a 
carboxylic acid proton which is created by the deprotection of the methyl ester when run 
through the column.    
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IR spectra taken in deuterated acetonitrile on salt plates. Formation of nitrosyl 
stretching frequency at 1862 cm-1 is observed while other salen-MeEs peaks remain 
unchanged other than the splitting of the C=N stretch from 1636 to having a 1635 and 1609 
cm-1. The extinction coefficient of Ru(NO)(salen-MeEs)Cl was taken in acetonitrile from 800-
200nm.  UV-vis  = 4.0 x 104  at max = 378nm. 
 
Scheme ii.4. Insertion of the ruthenium nitrosyl into the salophen-CO2CH3 ligand structure. 
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Figure ii.4. 1H NMR of Ru(NO)(Salophen-CO2CH3)Cl in acetonitrile on a 500 mHz Varian 
NMR. 
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Aii.3.4 Ru(NO)(Salen-OH)Cl 
 RuCl3(NO)∙H2O (0.0263 g, 0.103 mmoles) and salen-OH (0.0309 g, 0.103 mmoles) 
were placed in a three neck flask, vacuumed and back filled with argon three times to assure 
an air free starting flask. Distilled and degassed THF (30 mL) was added to the solution via 
cannula and the solution was heated and stirred in the dark.  After 20 minutes of heating and 
stirring, 0.02 mL (0.143 mmoles) of fully degassed triethylamine was added.  The solution 
was refluxed under argon for 3 hours in the dark.  The reaction was allowed to cool to room 
temperature and was filtered under argon via cannula (Scheme ii.5).  
 1H NMR 400 mHz Varian ((CD3)2SO) 9.7 (s, 2H), 7.51 (d, 2H), 6.51 (d, 2H), 6.33 
(s, 2H), 3.54 (q, 4H). ). (Figure ii.5). MS(ESI+): m/z (464.9 – H+)  463.96 is consistent with 
deprotinated RuCl(NO)(salen-OH) (Figure ii.6). FTIR (KBr) NO = 1851 cm-1. UV-vis 
(acetonitrile) max 276nm ( = 3.9 x 104 M-1 s-1). 
 
 
Scheme ii.5. Insertion of the ruthenium nitrosyl into the salen-OH ligand structure. 
Experiment conducted in the dark.  
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Figure ii.5. 1H NMR of Ru(NO)(Salen-OH)Cl in (CD3)2SO on a 400 mHz Varian NMR. 
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Figure ii.6. Low resolution negative ion mass spectrometry for RuCl(NO)(salen-OH) in water 
with ammonium hydroxide.  A mass of 463.96 is consistent with deprotinated 
RuCl(NO)(salen-OH). 
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Aii.3.5 Ru(NO)(Salophen- CO2CH3)Cl 
 0.3009 g salophen-MeEs and 0.0368 g NaH were combined and dissolved in 50 mL 
ethanol. The sample was sonicated for 5 minutes for the salophen to completely dissolve. The 
solution was heated and stirred for 30 minutes and purged with argon. 0.1778g Ru(NO)Cl3 • 
H2O was dissolved in 10 mL of ethanol and cannula added to the hot reaction flask in the dark 
under argon (Scheme ii.6).  
 The reaction was allowed to progress for 24 hours. The solution was removed from 
heat and allowed to cool. Stirring stopped and precipitate was allowed to fall out of solution. 
The solid was dried and 1H NMR was taken in d3-acetonitrile. Mass Spec data shows the full 
compound with a sodium cation with a signal at 622.05. 1H NMR 500 mHz Varian (CD3CN) 
9.23 (s, 2H), 8.44 (d, 2H), 8.20 (m, 2H), 8.04 (dd, 2H), 7.58 (m, 2H), 7.18 (d, 2H), 3.88 (s, 
6H) (Figure ii.7). Elemental Analysis C 43.9%, H 2.51%, N 6.58%. Theoretical 
[Ru(NO)(salophen-CO2CH3)Cl•NaCl], C 43.98%, H 2.77%, N 6.41%. MS(ESI+): m/z 
(596.99 + 23) 620.05 (M + Na+) (Figure ii.8). FTIR (KBr) NO = 1829 cm-1. UV-vis 
(acetonitrile) max 284nm ( = 6.0 x 104 M-1 s-1), 433 ( = 1.06 x 104 M-1 s-1) (Figure ii.9). 
 
Scheme ii.6. Synthesis of Ru(NO)(Salophen- CO2CH3)Cl. Synthesis completed in the dark. 
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Figure ii.7. 1H NMR of Ru(NO)(salophen-MeEs)Cl in acetonitrile. Protons designations are 
labeled with corresponding numbers. 
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Figure ii.8. Mass spectra, ESI+ for Ru(NO)(salophen-CO2CH3)Cl + Na
+  MW= 596.99 + 23. 
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Figure ii.9. Ru(NO)(salophen-MeEs)Cl in acetonitrile before (solid line) and after exposure 
to UV-lamp (dashed line). The LMCT band shifts from 432 nm to 422 nm after photolysis 
while the MLCT drops in intensity at 284 nm upon irradiation. 
Aii.4 Ruthenium Precursors 
Aii.4.6 RuCl2(PPh3)3  
 The synthesis was modified from the published work of T. A. Stephenson and G. 
Wilkinson.2 Dichlorotris(triphenylphosphine)ruthenium(II) was synthesized by dissolving 
0.0258 g RuCl3 (0.1244 mmol) and into 0.3269 g triphenylphosphine (1.246 mmol) 50mL of 
degassed methanol.  The solution was refluxed under inert atmosphere for 4 hours with 
stirring. The solution was allowed to cool to room temperature and stirring was stopped to 
allow for the product to precipitate. The methanol was removed using cannula filtration. The 
red powder was washed with ethyl ether and allowed to dry on vacuum. (Note: RuCl2(PPh3)3 
is extremely oxygen sensitive, this will oxidize from red to green at any oxygen exposure.)   
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Aii.4.7 Ru(salen)(PPh3)2 
 In the same flask as the RuCl2(PPh3)3 a 1:1 mole ratio of salen (0.065 g, 0.00024 mol) 
was added.  Distilled, degasses THF was cannula transferred into the reaction flask to dissolve 
compounds and begin heating. The triethylamine was fully deaerated by freeze/pump/thaw of 
approximately 1mL until there is no air present in the liquid, add 0.04 mL (0.286 mmoles) of 
triethylamine to the ruthenium solution with a lure lock syringe.  
 The reaction was allowed to reflux, under inert atmosphere for 3 hours then the 
solution was removed from heat and allowed to cool to room temperature. Supernatant was 
removed by cannula filtration and the product was fully dried under vacuum to produce a red 
solid.  Solid was transferred into an inert atmosphere glove box for storage.  
Aii.4 Quantum Yield Studies 
 Quantum yield studies were completed for Ru(NO)(salen-CO2CH3)Cl and 
Ru(NO)(salen-OH)Cl by monitoring the change in UV-visible spectra or by monitoring the 
production of NO on the Nitric Oxide Analyzer (Sievers 1080i NOA). Both methods 
underwent the same photochemical conditions of irradiation at λ = 365 nm in acetonitrile 
under an inert atmosphere, the results of the QY tests are discussed below.   
Aii.4.1 Nitric Oxide Quantum yield measurements for Ru(NO)(salen-CO2CH3)Cl and 
Ru(NO)(salen-OH)Cl  
 For each NO QY experiment, a 0.25 mM solution of either Ru(NO)(salen-CO2CH3)Cl 
or Ru(NO)(salen-OH)Cl was prepared in acetonitrile and an aliquot of 3 mL was used for each 
individual experiment. The sample was photolyzed in a 4-sided, Y-shaped cuvette which 
allows the carrier gas (helium, bubbled through 5 mL acetonitrile prior to entering the 
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photolysis cell) to flow through the cell and purge the experiment as NO is generated. The 
samples were irradiated at 365 nm with a mercury lamp. Ferrioxolate actinometry was used 
to calculate the photons of light emitted and the photolysis timing was controlled with a 
uniblitz optical shutter. After each photolysis, the Nitric Oxide Analyzer (NOA) was allowed 
to return to baseline for a minimum of 1 minute prior to the next irradiation time point. (A 
complete description of the Sievers 1080i NOA is described in Appendix 1.)The moles of NO 
were calculated from the calibration curve established on the NOA. 
 The moles of NO released versus the photons of light absorbed by the sample is plotted 
in Figures ii.10 and ii.11. Photolysis of Ru(NO)(salen-CO2CH3)Cl at 365 nm resulted in a 
ΦNO of 0.111 or 11.1% while the electron donating phenol groups lowered the ΦNO for 
Ru(NO)(salen-OH)Cl with a ΦNO of 0.0073 or 7.3%.  
 
Figure ii.10. QY Ru(NO)(salen-CO2CH3)Cl on the NOA irradiating at λ = 365 nm in 
acetonitrile under inert conditions.  
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Figure ii.11. QY Ru(NO)(salen-OH) on the NOA irradiating at λ = 365 nm in acetonitrile 
under inert conditions.  
Aii.4.2 Quantum yield measurements for Ru(NO)(salen-CO2CH3)Cl and Ru(NO)(salen-
OH)Cl 
For each QY experiment, a 0.25 mM solution of either Ru(NO)(salen-CO2CH3)Cl or 
Ru(NO)(salen-OH)Cl was prepared in acetonitrile and an aliquot of 3 mL was used for each 
individual experiment. The sample was photolyzed in a 4-sided, capped cuvette with a stir bar 
and was purged with argon, the sample was allowed to stir for 30 seconds after photolysis 
prior to taking the UV-visible spectra to allow the solution to equilibrate prior to measurement. 
The samples were irradiated at 365 nm with a mercury lamp. Ferrioxolate actinometry was 
used to calculate the photons of light emitted and the photolysis timing was controlled with a 
uniblitz optical shutter. The change in absorbance throughout the experiment were collected 
including the initial absorbance spectra.  
 The Ru(NO)(salen- CO2CH3)Cl had two new bands appear throughout photolysis at 
358 nm and 613 nm. The wavelength λ = 613 nm was monitored for the appearance of the 
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photo product resulting in a Φ365 of 0.130 (± 0.04). The Ru(NO)(salen-OH)Cl compound in 
solution, similarly showed the growth of two absorbance bands during photolysis at 276 nm 
and 687 nm. The Φ365 was measured by monitoring at 687 nm which has no absorbance in the 
original solution. Therefore, the Φ365 of Ru(NO)(salen-OH)Cl was 0.081 (± 0.012). 
 
Figure ii.12. Solution of Ru(NO)(salen- CO2CH3)Cl in acetonitrile. Upon photolysis and 
generation of the photoproduct, the growth of two peaks at 358 nm and 613 nm.  
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Figure ii.13. Solution of Ru(NO)(salen-OH)Cl in acetonitrile. Upon photolysis and 
generation of the photoproduct, the growth of a peak at 687 nm. 
Aii.4.3 Conclusion for QY Studies  
 Quantum yield studies have been presented here for two compounds, Ru(NO)(salen-
CO2CH3)Cl and Ru(NO)(salen-OH)Cl. As there are two products generated (the ruthenium-
photo product and the nitric oxide) two methods for calculating QYs have been utilized under 
inert conditions with irradiation at 365 nm. The first method measured the moles of NO 
produced while the second method measured the spectral change and formation of the 
ruthenium photoproduct which has a unique spectra from the unphotolyzed species (depicted 
in Figures ii.12 and ii.13). The two methods resulted in QY values within standard deviation 
and are shown in Table ii.1.  
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 Ru(NO)(salen-CO2CH3)Cl Ru(NO)(salen-OH)Cl 
Φ365 nm 
0.13 ± 0.04 
(monitoring 613 nm) 
0.081 ± 0.012 
(monitoring 687 nm) 
ΦNO 365 nm 0.111 ± 0.001 0.073 ± 0.001 
Table ii.1. Quantum yield measurements at 365 nm under inert conditions measured by 
spectral changes (Φ365 nm) or measured on the NOA by the release of nitric oxide (ΦNO 365nm). 
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